var title_f27_3_27696="Asymptomatic eye NAION";
var content_f27_3_27696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asymptomatic eye in a patient with nonarteritic anterior ischemic optic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fellow eye in a person with nonarteritic anterior ischemic optic neuropathy (NAION). Note the small cup.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Madhura Tamhankar, MD and Nicholas J Volpe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27696=[""].join("\n");
var outline_f27_3_27696=null;
var title_f27_3_27697="Thickening of distal ileum";
var content_f27_3_27697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Abdominal CT scan showing thickening of the distal ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ramos L, Alonso C, Guilarte M, et al. Anisakis simplex-induced small bowel obstruction after fish ingestion: preliminary evidence for response to parenteral corticosteroids. Clin Gastroenterol Hepatol 2005; 3:667. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27697=[""].join("\n");
var outline_f27_3_27697=null;
var title_f27_3_27698="MRI recurrent chondrosarcoma";
var content_f27_3_27698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Recurrent chondrosarcoma of the thoracic spine in a 70-year-old man",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial MRI sections through the thoracic spine, demonstrating the recurrent chondrosarcoma (white arrows) compressing the spinal cord (black arrows) and the soft tissue extension adjacent to the allograft. The tumor extended to the dural margin, and intraoperative radiation was administered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis J Hornicek, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27698=[""].join("\n");
var outline_f27_3_27698=null;
var title_f27_3_27699="Bacitracin and polymyxin B: Pediatric drug information";
var content_f27_3_27699=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin and polymyxin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11491?source=see_link\">",
"    see \"Bacitracin and polymyxin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/37/3669?source=see_link\">",
"    see \"Bacitracin and polymyxin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Poly-Bac&trade;;",
"     </li>",
"     <li>",
"      Polycin&trade;;",
"     </li>",
"     <li>",
"      Polysporin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      LID-Pack&reg;;",
"     </li>",
"     <li>",
"      Optimyxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11491?source=see_link\">",
"      see \"Bacitracin and polymyxin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo; to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; directly into conjunctival sac(s) every 3-4 hours depending on severity of the infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply a small amount of ointment or dusting of powder to the affected area 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Poly-Bac&trade;: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polycin&trade;: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: Bacitracin 500 units and polymyxin B 10,000 units per g in white petrolatum (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polysporin&reg;: Bacitracin 500 units and polymyxin B 10,000 units per g (0.9 g, 15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polysporin&reg;: Bacitracin 500 units and polymyxin B 10,000 units per g (10 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Do not use topical ointment in the eyes; avoid contact of tube tip with skin or eye",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial infections involving the conjunctiva and/or cornea caused by susceptible organisms; prevent infection in minor cuts, scrapes and burns",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betadine&reg; may be confused with Betagan&reg;, betaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local: Anaphylactoid reactions, burning, conjunctival erythema, itching, rash, swelling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polymyxin, bacitracin, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in overgrowth of nonsusceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Insignificant from intact skin or mucous membrane",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/37/3669?source=see_link\">",
"      see \"Bacitracin and polymyxin B: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use longer than 1 week unless directed by physician; ophthalmic ointment may cause blurred vision",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12977 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27699=[""].join("\n");
var outline_f27_3_27699=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045485\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045481\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138719\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138707\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045488\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045487\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138743\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138741\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045491\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045480\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298808\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138714\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138715\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413652\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045490\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045484\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11491?source=related_link\">",
"      Bacitracin and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/37/3669?source=related_link\">",
"      Bacitracin and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27700="Storz C Mac video laryngoscope";
var content_f27_3_27700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Storz C-Mac video laryngoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video laryngoscopes like the model pictured above use a camera positioned deep to the tongue and oropharynx to provide an excellent, wide angle view of the glottis.",
"    <div class=\"footnotes\">",
"     Image courtesy of KARL STORZ Endoskope, Germany.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27700=[""].join("\n");
var outline_f27_3_27700=null;
var title_f27_3_27701="Trachelectomy following supracervical hysterectomy";
var content_f27_3_27701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trachelectomy following supracervical hysterectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Rosanne M Kho, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Javier F Magrina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27701/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/3/27701/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30187289\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachelectomy to remove the cervical stump after prior supracervical hysterectomy is typically performed to manage cervical symptoms or disease that develops postoperatively. In a series of 70 consecutive women who underwent supracervical hysterectomy, 17 (24 percent) subsequently reported symptoms such as cyclical bleeding, pelvic pain, and dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/1\">",
"     1",
"    </a>",
"    ]. Postoperative cyclical vaginal bleeding often results from residual endometrium and has been reported by 5 to 20 percent of patients randomized to supracervical hysterectomy in trials comparing subtotal versus total hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Pain and dyspareunia may be due to adhesions, cervical fibroid, or consequences of morcellation of the uterine body, which can result in painful myometrial implants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    This topic will review the indications for trachelectomy after supracervical hysterectomy, as well as techniques and possible complications. Radical trachelectomy performed as fertility sparing surgery in women with early stage cervical cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=see_link\">",
"     \"Fertility sparing surgery for invasive cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187296\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trachelectomy is typically performed after prior supracervical hysterectomy to treat disease or symptoms referable to the cervical stump. It may also be performed in conjunction with other pelvic surgery (eg, oophorectomy, bowel resection). In the largest series of trachelectomy from a single institution (n = 310 cases from 1974 to 2003), the most common indications were [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolapse (52 percent)",
"     </li>",
"     <li>",
"      Pelvic mass (25 percent)",
"     </li>",
"     <li>",
"      Abnormal cervical cytology (12 percent)",
"     </li>",
"     <li>",
"      Bleeding (9 percent)",
"     </li>",
"     <li>",
"      Pelvic pain (7 percent)",
"     </li>",
"     <li>",
"      Non-cervical cancer (6 percent)",
"     </li>",
"     <li>",
"      Dyspareunia (3 percent)",
"     </li>",
"     <li>",
"      Other (7 percent)",
"     </li>",
"     <li>",
"      Multiple indications (18 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean duration of time between supracervical hysterectomy and trachelectomy was 21 years when the indication for trachelectomy was cervical cancer and 31 years when the indication was prolapse. Up to 1.5 percent of patients undergo trachelectomy within three months of their supracervical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187310\">",
"    <span class=\"h1\">",
"     VAGINAL VERSUS NON-VAGINAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surgical approach depends on the specific indications for trachelectomy, the need for concomitant procedures, and the presence of comorbidities.",
"   </p>",
"   <p>",
"    A laparoscopic, robotic, or open (laparotomy) abdominal approach is indicated when thorough abdominal exploration is necessary and surgical resection of abdominal or pelvic disease may be required. We use a laparoscopic or robotic approach in most patients with a pelvic mass, endometriosis, or pelvic pain. However, this requires patient positioning in steep Trendelenburg, which may not be tolerated by patients with cardiac hypertrophy or ischemia, abdominal distension, increased intracranial pressure, ongoing infusions for neuraxial anesthesia, recent eye surgery, or who are at increased risk of gastric reflux or aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. For these patients, an open approach is performed.",
"   </p>",
"   <p>",
"    If there are no specific indications for an abdominal approach, we perform trachelectomy vaginally because of its lower morbidity and faster recovery compared with the abdominal approach (see",
"    <a class=\"local\" href=\"#H30187340\">",
"     'Complications'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    In women with cervicovaginal prolapse, uterosacral ligament suspension (McCall&rsquo;s culdoplasty) and repair of the anterior and posterior vaginal compartments are also performed, as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H8286327#H8286327\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Uterosacral ligament suspension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the large series described above, the types and frequencies of indications for the abdominal and vaginal approaches were [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Abdominal trachelectomy",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic mass (65 percent)",
"     </li>",
"     <li>",
"      Non-cervical cancer (17 percent)",
"     </li>",
"     <li>",
"      Pain (12 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaginal trachelectomy",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolapse (74 percent)",
"     </li>",
"     <li>",
"      Abnormal cervical cytology smear (14 percent)",
"     </li>",
"     <li>",
"      Bleeding (9 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187498\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics are given prior to trachelectomy, for both vaginal and non-vaginal approaches (",
"    <a class=\"graphic graphic_table graphicRef87200 \" href=\"UTD.htm?12/1/12317\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For any approach, the surgeon should be prepared to perform adhesiolysis as loops of bowel attached to the bladder or the superior aspect of the cervical stump are common. We perform adhesiolysis sharply, without the use of electrosurgery in order to avoid potential risk of thermal injury to the bowel. &nbsp;",
"   </p>",
"   <p>",
"    Routine cystoscopy is performed at the end of the procedure to detect unrecognized full thickness bladder injury and ureteral entrapment, except in cases where ureteral dissection was performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187317\">",
"    <span class=\"h2\">",
"     Vaginal trachelectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed in the dorsal lithotomy position using candy cane stirrups. We attach a Magrina-Bookwalter vaginal retractor system to the foot of the operating table to maximize exposure with self-retaining retractors (",
"    <a class=\"graphic graphic_picture graphicRef87612 \" href=\"UTD.htm?22/36/23108\">",
"     picture 1",
"    </a>",
"    ). The following synopsis describes our approach to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grasp the anterior and posterior lips of the cervix with Jacobs&rsquo; tenaculum for traction",
"     </li>",
"     <li>",
"      Inject 1%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine or diluted vasopressin submucosally and into the pericervical areas to reduce bleeding",
"     </li>",
"     <li>",
"      Make a circumferential incision on the cervix with a #10-blade, taking care to avoid the distal margins of the bladder anteriorly and the rectovaginal junction posteriorly",
"     </li>",
"     <li>",
"      Retract the anterior vaginal wall with a curved anterior blade retractor",
"     </li>",
"     <li>",
"      Sharply dissect the vaginal mucosa off the cervical stump using Mayo scissors",
"     </li>",
"     <li>",
"      After the full thickness of the anterior vaginal mucosa is dissected from the cervix, push the bladder pillars superiorly and laterally with the index finger to ensure safe subsequent placement of clamps on the cardinal ligaments. Ideally, delay entry into the abdominal cavity anteriorly until good descensus of the cervical stump and visualization of the vesico-peritoneal fold are achieved.",
"     </li>",
"     <li>",
"      With the cervix acutely deflected anteriorly, expose the posterior cul-de-sac by sharp dissection with the Mayo scissors",
"     </li>",
"     <li>",
"      We prefer sealing and dividing the uterosacral ligaments with a vessel-sealing device, such as the LigaSure Impact; however, the ligaments can be divided by clamping with a Heaney clamp, sharp division, and suture-ligation. The lowest portion of one cardinal ligament is divided similarly, which allows further descent of the cervix.",
"     </li>",
"     <li>",
"      Insert an index finger through the posterior cul-de-sac and feel for bowel or omental adhesions attached to the cervical stump and adjacent peritoneum. These are bluntly or sharply divided.",
"     </li>",
"     <li>",
"      Place the index finger along the anterior superior cervix, positioning the tip against the peritoneum anteriorly to allow safe entry to the anterior cul-de-sac as the peritoneum is cut.",
"     </li>",
"     <li>",
"      Withdraw the index finger and insert into the anterior cul-de-sac. Locate the ureters by palpating each one against a Deaver retractor placed against the vagina at the three o&rsquo;clock and nine o&rsquo;clock positions. Clamp and divide the remaining cardinal ligaments away from the ureters. We routinely perform McCall&rsquo;s suture plication of the uterosacral ligaments to the midportion and corners of the vaginal cuff to prevent future prolapse of the vaginal apex [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/10\">",
"       10",
"      </a>",
"      ]. Concomitant culdoplasty, anterior repairs, and posterior repairs can then be performed, if applicable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H8286327#H8286327\">",
"       \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Uterosacral ligament suspension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"       \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Close the vaginal cuff using a series of interrupted 2-0 delayed absorbable sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187324\">",
"    <span class=\"h2\">",
"     Laparoscopic and robotic trachelectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest bowel preparation for patients who will be undergoing a laparoscopic or robotic approach because in our experience it improves pelvic exposure. We use a commercially available preparation kit (HalfLytely) consisting of two liters of sulfate free electrolyte lavage solution (identical to the commercial preparation \"NuLYTELY\") plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    tablets.",
"   </p>",
"   <p>",
"    The patient is placed in the modified dorsal lithotomy position and directly on an anti-skid material to prevent sliding during steep Trendelenburg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/11\">",
"     11",
"    </a>",
"    ]. She lies with her skin directly against the eggcrate material, and her arms tucked safely at her sides (",
"    <a class=\"graphic graphic_picture graphicRef87620 \" href=\"UTD.htm?3/14/3302\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A three-way bladder catheter is inserted so the bladder can be distended to help distinguish its borders from the cervix. A vaginal probe or a cervical cup is inserted to define the area for colpotomy.",
"   </p>",
"   <p>",
"    The following synopsis describes our approach to the procedure, which is the same whether performed conventionally or robotically. The robotic system was designed to overcome many of the challenges of conventional laparoscopy. The availability of the three-dimensional view, articulation of the instrument tips, downscaling, and abolition of tremor with robotics facilitates dissection and intracorporeal suturing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make a small transumbilical incision and enter the peritoneal cavity",
"     </li>",
"     <li>",
"      Place trocars, depending on the approach (robotic or laparoscopic) (",
"      <a class=\"graphic graphic_figure graphicRef87621 \" href=\"UTD.htm?24/17/24862\">",
"       figure 1",
"      </a>",
"      ). The surgeon should be prepared to handle any adhesions, which are common given the patient&rsquo;s previous supracervical hysterectomy.",
"     </li>",
"     <li>",
"      With the bladder distended, develop the vesicovaginal space and dissect at least 2 cm beyond the intended colpotomy incision.",
"     </li>",
"     <li>",
"      Identify the ureter on the lateral pelvic peritoneum and trace it to where it crosses the uterine artery. The ureter may have to be mobilized and lateralized prior to dividing the uterine artery. If a vaginal probe is used, make the colpotomy incision at the junction where the cervix ends and the bulge of the vaginal probe begins. If a cervical cup is used, the ring is easily palpated with the laparoscopic instrument or visualized with the robotic approach.",
"     </li>",
"     <li>",
"      Colpotomy is performed with a monopolar hook, spatula, or scissors, depending on the surgeon&rsquo;s preference. Because vaginal cuff dehiscence can occur after trachelectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/12\">",
"       12",
"      </a>",
"      ], we minimize over-coagulation of tissue as necrotic tissue invariably delays vaginal cuff healing.",
"     </li>",
"     <li>",
"      Close the vaginal cuff using 2-0 or 0 delayed-absorbable suture:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place the needle at least 5 mm away from the coagulated edge of the anterior and posterior vaginal walls and include the full-thickness of both walls",
"     </li>",
"     <li>",
"      Incorporate the utero-sacral ligaments into the vaginal cuff angles to support the vaginal vault",
"     </li>",
"     <li>",
"      Place a second continuous suture or additional figure-of-eight sutures for reinforcement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187340\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on complications and outcome of non-radical trachelectomy is limited because most reports are small retrospective case series or descriptions of single cases, and the procedures were performed for a variety of indications, by different approaches, and often with additional surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series reported by a single institution included 310 cases of trachelectomy after supracervical hysterectomy performed for a variety of indications (see",
"    <a class=\"local\" href=\"#H30187296\">",
"     'Indications'",
"    </a>",
"    above), and included patients who had benign or malignant disease and who underwent vaginal or abdominal procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"     6",
"    </a>",
"    ]. The overall complication rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection (9 percent)",
"     </li>",
"     <li>",
"      Perioperative bleeding (9 percent)",
"     </li>",
"     <li>",
"      Urinary retention (6 percent)",
"     </li>",
"     <li>",
"      Intraoperative bowel injury (2 percent)",
"     </li>",
"     <li>",
"      Urinary tract infection (1 percent)",
"     </li>",
"     <li>",
"      Thromboembolism (1 percent)",
"     </li>",
"     <li>",
"      Other (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intra- and perioperative complications were more common with the abdominal approach than with the vaginal approach (43 versus 20 percent, p&lt;0.001) and there were significantly more infections and perioperative bleeding in the abdominal group. Urinary retention only occurred in patients who had a concomitant anterior colporrhaphy and Kelly-Kennedy plication.",
"   </p>",
"   <p>",
"    No studies have specifically compared complication rates for laparoscopic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    robotic trachelectomy versus the vaginal or the open abdominal approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107272955\">",
"    <span class=\"h1\">",
"     CERVICAL HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the large series described above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"     6",
"    </a>",
"    ], histology of the cervical stump revealed cervicitis (53 percent), normal (32 percent), squamous dysplasia (6 percent), cancer (5 percent), adenocarcinoma (1 percent), fibroids (1 percent), and other (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"     6",
"    </a>",
"    ]. It should be noted that these procedures were performed between 1974 and 2003, which might be a factor in the type and distribution of pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30187347\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease or symptoms referable to the cervical stump after supracervical hysterectomy can be treated by trachelectomy. Prolapse, pain, cyclical bleeding, and cervical abnormalities are common indications. (See",
"      <a class=\"local\" href=\"#H30187296\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal surgical approach depends on the specific indications for trachelectomy, the need for concomitant procedures, and the presence of comorbidities. An abdominal approach (laparoscopic, robotic, or open) is indicated when thorough abdominal exploration is necessary and surgical resection of abdominal or pelvic disease may be required. If there are no specific indications for an abdominal approach, we perform trachelectomy vaginally because of its lower morbidity and faster recovery. (See",
"      <a class=\"local\" href=\"#H30187296\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing vaginal trachelectomy, we routinely perform McCall&rsquo;s suture plication of the uterosacral ligaments to the midportion and corners of the vaginal cuff to prevent future prolapse of the vaginal apex. (See",
"      <a class=\"local\" href=\"#H30187317\">",
"       'Vaginal trachelectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A key step in avoiding complications during trachelectomy is to identify the ureters before dividing the cardinal ligaments in the vaginal approach and before dividing the cervical branch of the uterine artery in the abdominal approach. Identification of adhesions and careful adhesiolysis is another important step for reducing complications. (See",
"      <a class=\"local\" href=\"#H30187498\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/1\">",
"      Okaro EO, Jones KD, Sutton C. Long term outcome following laparoscopic supracervical hysterectomy. BJOG 2001; 108:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/2\">",
"      Thakar R, Ayers S, Clarkson P, et al. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med 2002; 347:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/3\">",
"      Gimbel H, Zobbe V, Andersen BM, et al. Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. BJOG 2003; 110:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/4\">",
"      Learman LA, Summitt RL Jr, Varner RE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 2003; 102:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/5\">",
"      Hilger WS, Magrina JF. Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy. Obstet Gynecol 2006; 108:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/6\">",
"      Hilger WS, Pizarro AR, Magrina JF. Removal of the retained cervical stump. Am J Obstet Gynecol 2005; 193:2117.",
"     </a>",
"    </li>",
"    <li>",
"     Peruzzi WT, Candido KD. Respiratory care. In: Trauma: Critical Care, Wilson WC, Grande CM, Hoyt DB.  (Eds), Informa Health Care USA Inc, New York 2007. Vol 2, p.492.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/8\">",
"      Perrin M, Fletcher A. Laparoscopic abdominal surgery. Contin Educ Anaesth Crit Care Pain 2004; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/9\">",
"      Sheth SS. Vaginal excision of cervical stump. J Obstet Gynaecol 2000; 20:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/10\">",
"      Margulies RU, Rogers MA, Morgan DM. Outcomes of transvaginal uterosacral ligament suspension: systematic review and metaanalysis. Am J Obstet Gynecol 2010; 202:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/11\">",
"      Klauschie J, Wechter ME, Jacob K, et al. Use of anti-skid material and patient-positioning to prevent patient shifting during robotic-assisted gynecologic procedures. J Minim Invasive Gynecol 2010; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/12\">",
"      Kho RM, Akl MN, Cornella JL, et al. Incidence and characteristics of patients with vaginal cuff dehiscence after robotic procedures. Obstet Gynecol 2009; 114:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/13\">",
"      El-Zohairy MA. Trachelectomy: a review of 15 cases. J Egypt Natl Canc Inst 2010; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/14\">",
"      Parkar RB, Hassan MA, Otieno D, Baraza R. Laparoscopic Trachelectomy for Cervical Stump 'Carcinoma in situ'. J Gynecol Endosc Surg 2011; 2:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/15\">",
"      Nezhat CH, Rogers JD. Robot-assisted laparoscopic trachelectomy after supracervical hysterectomy. Fertil Steril 2008; 90:850.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/16\">",
"      Nezhat CH, Nezhat F, Roemisch M, et al. Laparoscopic trachelectomy for persistent pelvic pain and endometriosis after supracervical hysterectomy. Fertil Steril 1996; 66:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27701/abstract/17\">",
"      Pasley WW. Trachelectomy: a review of fifty-five cases. Am J Obstet Gynecol 1988; 159:728.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16668 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27701=[""].join("\n");
var outline_f27_3_27701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30187347\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187289\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187296\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187310\">",
"      VAGINAL VERSUS NON-VAGINAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187498\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30187317\">",
"      Vaginal trachelectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30187324\">",
"      Laparoscopic and robotic trachelectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187340\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107272955\">",
"      CERVICAL HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30187347\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/16668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16668|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/17/24862\" title=\"figure 1\">",
"      Trocar positions for robotic pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16668|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/36/23108\" title=\"picture 1\">",
"      Magrina-Bookwalter vaginal retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/14/3302\" title=\"picture 2\">",
"      Patient position for laparoscopic or robotic trachelectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/1/12317\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gynecologic and obstetric surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=related_link\">",
"      Fertility sparing surgery for invasive cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9337?source=related_link\">",
"      Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27702="Herpetic stomatitis";
var content_f27_3_27702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Herpetic stomatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 496px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These three children demonstrate the spectrum of oral infection with herpes simplex virus, which ranges from asymptomatic to severe.",
"    <br/>",
"    (A) The first patient has a single vesicle on his tongue.",
"    <br/>",
"    (B) The second manifests widespread labial lesions.",
"    <br/>",
"    (C) The third patient shows dissemination to the face. In the young girl with facial involvement, fluorescein dye is dripping from the left eye after its instillation in an attempt to identify the typical dendritic ulcer seen with herpetic keratitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27702=[""].join("\n");
var outline_f27_3_27702=null;
var title_f27_3_27703="Flurazepam: Drug information";
var content_f27_3_27703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/47/33524?source=see_link\">",
"    see \"Flurazepam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/24/12678?source=see_link\">",
"    see \"Flurazepam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flurazepam&reg;;",
"     </li>",
"     <li>",
"      Dalmane&reg;;",
"     </li>",
"     <li>",
"      Som Pam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insomnia (short-term treatment): Oral: 15-30 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F173083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/24/12678?source=see_link\">",
"      see \"Flurazepam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnotic: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;15 years: Dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;15 years: 15 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 15 mg at bedtime. Avoid use if possible.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 15 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F173101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016721s077lbl.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016721s077lbl.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurazepam may be confused with temazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dalmane&reg; may be confused with Demulen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, flushing, hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, ataxia, confusion, depression, dizziness, drowsiness, euphoria, faintness, falling, hallucinations, hangover effect, headache, irritability, lightheadedness, memory impairment, nervousness, paradoxical reactions, restlessness, slurred speech, staggering, talkativeness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased/decreased, bitter taste, constipation, diarrhea, GI pain, heartburn, nausea, salivation increased/excessive, upset stomach, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, cholestatic jaundice, total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Body/joint pain, dysarthria, reflex slowing, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, burning eyes, difficulty focusing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use (generally &gt;10 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as flurazepam), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F173061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum levels and response to flurazepam may be increased by grapefruit juice, but unlikely because of flurazepam's high oral bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3921683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although information specific to flurazepam has not been located, all benzodiazepines are assumed to cross the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines. Neonatal depression has been observed, specifically following exposure to flurazepam when used maternally for 10 consecutive days prior to delivery. Serum levels of N-desalkylflurazepam were measurable in the infant during the first 4 days of life. Use of flurazepam during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F173073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11229306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Flurazepam HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $28.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $34.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F173045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0-4 ng/mL (SI: 0-9 nmol/L); Metabolite N-desalkylflurazepam: 20-110 ng/mL (SI: 43-240 nmol/L); Toxic: &gt;0.12 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dalmadorm (BR, CH, GH, GR, GT, HK, ID, IT, KE, NL, NO, PT, SG, TH, TW, TZ, UG, ZM);",
"     </li>",
"     <li>",
"      Dalmane (GB, GH, IE, KE, TZ, UG, ZM);",
"     </li>",
"     <li>",
"      Dormodor (ES, ZA);",
"     </li>",
"     <li>",
"      Flunox (IT);",
"     </li>",
"     <li>",
"      Fluralema (VE);",
"     </li>",
"     <li>",
"      Fluraz (IN);",
"     </li>",
"     <li>",
"      Fluzepam (HR);",
"     </li>",
"     <li>",
"      Fordrim (AR);",
"     </li>",
"     <li>",
"      Insumin (JP);",
"     </li>",
"     <li>",
"      Manlsum (TW);",
"     </li>",
"     <li>",
"      Nergart (JP);",
"     </li>",
"     <li>",
"      Noctosom (IL);",
"     </li>",
"     <li>",
"      Somlan (AR);",
"     </li>",
"     <li>",
"      Staurodorm (AT, BE, DE, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypnotic: 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 7-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to N-desalkylflurazepam (active) and N-hydroxyethylflurazepam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flurazepam: 2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desalkylflurazepam:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Single dose: 74-90 hours; Multiple doses: 111-113 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elderly (61-85 years): Single dose: 120-160 hours; Multiple doses: 126-158 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desalkylflurazepam: 10.6 hours (range: 7.6-13.6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-hydroxyethylflurazepam: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine: N-hydroxyethylflurazepam (22% to 55%); N-desalkylflurazepam (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper SF and Drolet D, &ldquo;Protein Binding of Flurazepam and Its Major Metabolites in Plasma,&rdquo;",
"      <i>",
"       Curr Ther Res",
"      </i>",
"      , 1982, 32(5):757-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenblatt DJ, Harmatz JS, Engelhardt N, et al, &ldquo;Pharmacokinetic Determinants of Dynamic Differences Among Three Benzodiazepine Hypnotics: Flurazepam, Temazepam, and Triazolam,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1989, 46(4):326-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/2564763/pubmed\" id=\"2564763\" target=\"_blank\">",
"        2564763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maletta G, Mattox KM, and Dysken M, &ldquo;Guidelines for Prescribing Psychoactive Drugs in the Elderly: Part 1,&rdquo;",
"      <i>",
"       Geriatrics",
"      </i>",
"      , 1991, 46(9):40-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/1889756/pubmed\" id=\"1889756\" target=\"_blank\">",
"        1889756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reidenberg MM, Levy M, Warner H, et al, &ldquo;Relationship Between Diazepam Dose, Plasma Level, Age, and Central Nervous System Depression,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1978, 23(4):371-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/630787/pubmed\" id=\"630787\" target=\"_blank\">",
"        630787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruff RL, Kutt H, and Hafler D, &ldquo;Prolonged Benzodiazepine Coma,&rdquo;",
"      <i>",
"       N Y State J Med",
"      </i>",
"      , 1981, 81(5):776-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/6111773/pubmed\" id=\"6111773\" target=\"_blank\">",
"        6111773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stringer MD, &ldquo;Adult Respiratory Distress Syndrome Associated With Flurazepam Overdose,&rdquo;",
"      <i>",
"       J R Soc Med",
"      </i>",
"      , 1985, 78(1)1:74-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/3/27703/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8469 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-CBA3D06F7A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27703=[""].join("\n");
var outline_f27_3_27703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173099\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173069\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173083\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173070\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896232\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896233\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173044\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173028\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173101\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874503\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173048\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173108\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173097\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173051\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173032\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173095\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173061\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3921683\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173073\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229306\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173053\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173041\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173045\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038621\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173031\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173050\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/47/33524?source=related_link\">",
"      Flurazepam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/24/12678?source=related_link\">",
"      Flurazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27704="Simple and complex renal cysts in adults";
var content_f27_3_27704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Simple and complex renal cysts in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27704/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Jonathan B Kruskal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27704/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/3/27704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cysts result from genetic or nongenetic processes, and occur in a variety of diseases in adults and children. The most common causes of radiologically evident renal cysts in adults are simple renal cysts, which will be discussed here, autosomal dominant polycystic kidney disease, and, acquired cystic disease in patients with end-stage renal disease after several years of dialysis, particularly hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smaller cysts, usually less than 1 cm in diameter, also occur in medullary sponge kidney, autosomal recessive polycystic kidney disease, and autosomal dominant interstitial kidney disease (previously called medullary cystic kidney disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link\">",
"     \"Medullary sponge kidney\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other unusual causes of renal cysts in adults are von Hippel-Lindau disease, tuberous sclerosis complex, and nephronophthisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple renal cysts are commonly observed in normal kidneys, with an increasing incidence as individuals age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/1\">",
"     1",
"    </a>",
"    ]. They are benign asymptomatic lesions that rarely require treatment.",
"   </p>",
"   <p>",
"    The primary clinical concern is accurately distinguishing simple renal cysts from complex renal cysts that may harbor neoplastic masses. Based upon the initial radiographic evaluation, further study may or may not be required, and some complex lesions that cannot be characterized noninvasively require surgical excision for diagnosis.",
"   </p>",
"   <p>",
"    An overview of the renal cyst classification system, our recommended approach to complex renal cysts in adults, and a discussion of simple renal cysts are presented in this topic review. The evaluation of a solid renal mass is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BOSNIAK CLASSIFICATION OF RENAL CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidental finding of lesions in the renal parenchyma is common with the increased use of imaging procedures. Such lesions are usually simple benign renal cysts, complex renal cysts, or neoplasms, although the disorders previously described should also be considered, when appropriate. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To help diagnose and manage these lesions, the Bosniak renal cyst classification system was created [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"     2",
"    </a>",
"    ]. Based upon morphologic and enhancement characteristics with CT scanning, cystic renal masses are placed into one of five different categories (",
"    <a class=\"graphic graphic_table graphicRef67087 \" href=\"UTD.htm?14/61/15324\">",
"     table 1",
"    </a>",
"    ). The presence of true contrast enhancement of the lesion (a minimum increased attenuation of 10 to 15 Hounsfield units) is the most important characteristic separating categories III and IV, which are associated with malignancy in 40 to 90 percent, from the categories I, II, and IIF, which are typically benign processes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category I &mdash; This is a benign simple cyst with a thin wall without septa, calcifications, or solid components. It has the density of water and does not enhance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Simple renal cysts'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Category II &mdash; These are benign cystic lesions in which there may be a few thin septa; the wall or septa may contain fine calcification or a short segment of slightly thickened calcification. This category also includes uniformly high attenuating lesions that are less than 3 cm in diameter, well marginated, and non-enhancing.",
"     </li>",
"     <li>",
"      Category IIF &mdash; These cysts, which are generally well marginated, are more complicated than category II, but less so than category III. They may have multiple thin septa or minimal smooth thickening of the septa or wall, which may contain calcification that may also be thick and nodular. There is no measurable contrast enhancement. However, these lesions may have perceived enhancement of the septa or wall, which is due to only subjective (and not measurable) enhancement when the unenhanced and contrast-enhanced images are compared. This category also includes totally intrarenal nonenhancing high attenuating lesions that are more than 3 cm in diameter. These cysts require follow-up to ascertain that they are non-malignant.",
"     </li>",
"     <li>",
"      Category III &mdash; These are indeterminate cystic masses that have thickened irregular or smooth walls or septa. Measurable enhancement is present. Approximately 40 to 60 percent are malignant (cystic renal cell carcinoma and multiloculated cystic renal cell carcinoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. The remainder, such as hemorrhagic cysts, chronic infected cysts, and multiloculated cystic nephroma, are benign.",
"     </li>",
"     <li>",
"      Category IV &mdash; These lesions (85 to 100 percent of which are malignant) have all the characteristics of category III cysts plus they contain enhancing soft-tissue components that are adjacent to and independent of the wall or septum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77721 \" href=\"UTD.htm?36/42/37551\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT BY BOSNIAK CATEGORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a general approach to the evaluation of renal cystic lesions based upon initial classification according to the Bosniak CT system:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Category I and II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation of Bosniak category I and II lesions is generally not required. In certain instances, repeat ultrasonography at 6 to 12 months to assure stability and a correct diagnosis may be considered. If the clinician is unable to distinguish between a category II and IIF cyst, follow-up imaging is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Category IIF and III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to renal cystic lesions with indeterminate findings on ultrasonography and CT scanning is uncertain. These lesions are usually Bosniak category IIF or III. As previously mentioned, however, some category II lesions will be included in this category because the features often rely on the quality of the CT scan and the expertise of the radiologist; marked interobserver variation has also been noted when attempting to identify class II lesions that can be safely monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Category IIF cysts deserve follow-up imaging (hence the \"F\") to document stability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"     2",
"    </a>",
"    ]. With this approach, follow-up CT studies are an effective means for managing such complex cysts, in which the absence of change supports benign disease, while progression suggests a neoplastic process. The effectiveness of this approach was best shown in a report of 42 such patients who had follow-up examinations for two years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/6\">",
"     6",
"    </a>",
"    ]. Two lesions became more complex with thicker septa; both were found to be cystic neoplasms at surgery. This strategy therefore prevented unnecessary surgery in 95 percent (40 of 42 patients).",
"   </p>",
"   <p>",
"    The management of Bosniak category III lesions is controversial. Some authorities recommend that all Bosniak category III lesions undergo surgical evaluation, given the high incidence of malignancy (40 to 54 percent) with these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In addition, if the radiologist is unable to clearly distinguish a category IIF from a III lesion, they advocate placing the lesion into the higher category that requires surgery (category III), particularly if a partial nephrectomy is anatomically possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, with this approach to category III lesions, there would be a significant number of unnecessary surgeries since a significant percentage of patients with indeterminate lesions have benign lesions. To avoid this, two additional modalities, MRI and image-guided biopsy, have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/3,4,8-11\">",
"     3,4,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is typically used to evaluate patients with indeterminate lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. In addition to signal characteristics, MRI evaluates the same morphologic findings as described above for CT scanning: wall thickening, nodularity, septa, and enhancement. One difference is that MRI does not detect calcification. MRI is especially useful for characterizing internal contents of cysts, such as hemorrhage or mucin, and is more sensitive than both ultrasonography and CT in showing enhancement of internal septations.",
"   </p>",
"   <p>",
"    The potential value of this approach was illustrated in a series of 37 patients with 55 complex cystic renal lesions who underwent T1-weighted, T2-weighted, and gadolinium-enhanced MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/9\">",
"     9",
"    </a>",
"    ]. The following frequencies of malignancy were noted with specific radiographic abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      22 percent of 37 lesions that contained fluid of heterogeneous signal intensity",
"     </li>",
"     <li>",
"      44 percent of 32 lesions with intense mural (ie, cyst wall) enhancement",
"     </li>",
"     <li>",
"      63 percent of 16 lesions with mural irregularity",
"     </li>",
"     <li>",
"      71 percent of 14 lesions with a thick wall (&gt;2 mm)",
"     </li>",
"     <li>",
"      75 percent of four lesions with mural masses or nodules, and 50 percent of four lesions with septa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of mural irregularity and intense mural enhancement had the highest correlation with malignancy.",
"   </p>",
"   <p>",
"    Serial MRI examinations at 3, 6, and 12 months are warranted in patients with indeterminate lesions on gadolinium-enhanced MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Percutaneous needle biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative needle biopsies have generally",
"    <strong>",
"     not",
"    </strong>",
"    been recommended for resectable renal lesions because of concern about seeding of the peritoneum. However, biopsy is required prior to percutaneous cryoablation of renal masses. The evaluation of solid renal masses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of biopsy in evaluating an indeterminate renal mass or cyst is likely to grow, as such masses are increasingly being identified with the widespread use of CT and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/12\">",
"     12",
"    </a>",
"    ]. In patients with indeterminate imaging studies, percutaneous image-guided biopsy appears to be safe and can provide a diagnosis in up to 80 percent cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/4,5,12-14\">",
"     4,5,12-14",
"    </a>",
"    ]. This was illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated 28 patients with a complex cystic renal mass on CT scan who underwent image-guided biopsy: 17 (61 percent) had a malignant lesions (16 renal cell carcinoma, one lymphoma); and 11 had benign disease (six hemorrhagic cysts, three inflammatory cysts, one metanephric adenoma, and one cystic oncocytoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/4\">",
"       4",
"      </a>",
"      ]. The biopsy diagnosis was confirmed in all 17 patients who underwent surgical resection. There was no interval radiologic change at a minimum of one year in the ten patients with benign lesions who did not undergo surgery.",
"     </li>",
"     <li>",
"      A second study evaluated 517 patients in whom image-guided biopsy was performed for renal mass lesions that were classified as indeterminate by imaging (7.2 percent of renal masses). A diagnosis was established in 79 percent, with a malignant lesion found in 44 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/5\">",
"       5",
"      </a>",
"      ]. A false diagnosis was made in 1.2 percent, while a diagnosis could not be established by biopsy in 17 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;With category IIF lesions, we recommend making every attempt to obtain prior studies for purposes of comparison. If such studies are unavailable, many radiologists would recommend an additional imaging study (typically a good quality contrast-enhanced MRI) for further characterization.",
"   </p>",
"   <p>",
"    With category III lesions, we also try to obtain prior studies for purposes of comparison. In the absence of prior studies or if symptomatic or associated with hematuria, we recommend further imaging evaluation with a good quality contrast-enhanced MRI. If the lesion is still indeterminate, we obtain a surgical consult. Such lesions are either removed or closely followed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Category IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Category IV lesions require surgery, with approximately 85 to 100 percent being malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2,3,15,16\">",
"     2,3,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SIMPLE RENAL CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple renal cysts are observed frequently in normal kidneys. They are the most common renal masses, accounting for roughly 65 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/17\">",
"     17",
"    </a>",
"    ]. They may be solitary, or multiple and bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/15,17-19\">",
"     15,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of a solid renal mass is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of simple renal cysts varies with the population studied and the imaging modality utilized. These cysts occur most often in patients over the age of 50, and are more common in men compared with women, as determined from postmortem examination, renal ultrasonography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/17,18,20-23\">",
"     17,18,20-23",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1948 potential kidney donors, a cortical medullary or parapelvic cyst &ge;5 mm was detected by CT in 12, 14, and 2.8 percent of individuals, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/24\">",
"       24",
"      </a>",
"      ]. The prevalence of cortical or medullary cysts was higher among subjects aged 50 to 75 years compared with those aged 18 to 49 years (33 versus 12 for cortical cysts, and 17 versus 12 percent for medullary cysts, respectively). Cortical cysts were more common among men than women (23 versus 15 percent, respectively).",
"     </li>",
"     <li>",
"      A Japanese study of 14,314 individuals undergoing multiphasic health screening programs found at least one renal cyst on ultrasonography in 1700 (12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/22\">",
"       22",
"      </a>",
"      ]. A seven-fold increase in prevalence was noted from the fourth to the eighth decade of life (5 to 36 percent). The majority of cysts increased in size over time (2.18 mm per year).",
"     </li>",
"     <li>",
"      One report evaluated 729 patients who underwent ultrasonography for reasons unrelated to the urinary tract [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/18\">",
"       18",
"      </a>",
"      ]. The incidence (in percent) of at least one renal cyst according to age and gender was:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      15 to 29 years of age &mdash; 0 (males); 0 (females)",
"     </li>",
"     <li>",
"      30 to 49 &mdash; 1.9; 1.4",
"     </li>",
"     <li>",
"      50 to 69 &mdash; 15; 6.7",
"     </li>",
"     <li>",
"      &gt;70 &mdash; 32.3; 14.6",
"      <br/>",
"      <br/>",
"      In this report, bilateral cysts were much less common and were rare in subjects under age 50.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 617 adult patients undergoing contrast-enhanced abdominal CT scans unrelated to suspected pathology in the kidney found 213 simple renal cysts (41 percent), with significant increases in number and size of cysts with increasing age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple renal cysts are oval or round in shape of varying size, ranging from less than one cm to greater than 10 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/25\">",
"     25",
"    </a>",
"    ]. The lining of the cyst is a single epithelial cell layer without renal elements. There is a clear to straw colored fluid that resembles a plasma ultrafiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple cysts may be solitary, or multiple and bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/15,17-19\">",
"     15,17-19",
"    </a>",
"    ]. They typically produce no symptoms or signs. The clinical significance of simple cysts is not completely clear. Most nephrologists have long believed cysts to be of little significance. However in the study cited above of healthy potential kidney donors, after adjusting for age and sex, cysts &ge;5 mm were associated with higher albumin excretion, hypertension and hyperfiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/24\">",
"     24",
"    </a>",
"    ]. An association with hypertension has also been reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], although a study of over 1000 patients found no increase in the incidence of hypertension, flank pain, hematuria, or proteinuria when compared to matched controls without cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless obstruction is present, simple cysts do not compromise renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/29\">",
"     29",
"    </a>",
"    ]. However, limited evidence suggests that younger patients with simple renal cysts may have relatively reduced (but still normal) renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple cysts may rarely be associated with rupture (hemorrhage), hematuria, pain, abdominal mass, infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rupture (hemorrhage) of a simple cyst can cause hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      flank pain. In one of the largest series of 25 patients with rupture, 21 and 17 had hematuria and flank pain, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/32\">",
"       32",
"      </a>",
"      ]. Spontaneous rupture occurred in 21 patients, while blunt abdominal or iatrogenic (during a procedure) trauma caused the rupture in the remaining four individuals. Communication with the collecting system spontaneously closed in 11 patients, but remained in two.",
"     </li>",
"     <li>",
"      Infection of a simple renal cyst, a rare form of renal abscess, can occur. The clinical features of an infected simple renal cyst are the same as those of renal abscess, which are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"       \"Renal and perinephric abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compression of surrounding parenchyma may rarely cause angiotensin-dependent hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/31,33\">",
"       31,33",
"      </a>",
"      ]. In a retrospective review of 22 cases in the literature, removal or cyst aspiration cured or lowered blood pressure in 15 and 2 patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/33\">",
"       33",
"      </a>",
"      ]. The drop in blood pressure was closely related to reduced activity of the renin angiotensin system in the involved kidney, which harbored a large cyst in all cases.",
"      <br/>",
"      <br/>",
"      Despite this observation, the presence of hypertension in patients with simple cysts is most commonly the result of processes independent of the cyst, given that both simple cysts and hypertension are frequently observed among older individuals.",
"     </li>",
"     <li>",
"      Simple cysts may rarely cause calyceal or renal pelvic obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple renal cysts have characteristic changes on ultrasonography and computer tomography (CT). Given that most simple cysts are asymptomatic, the initial imaging study that detects such a cyst is commonly ultrasonography, which was usually performed for reasons unrelated to the urinary tract. If basic ultrasonography criteria for a benign simple cyst are met, further study is not required.",
"   </p>",
"   <p>",
"    A CT scan should be performed if the ultrasonogram is equivocal, if calcifications or septae are seen, or if multiple cysts are clustered in a pattern that could mask an underlying carcinoma. Based upon findings on CT scanning, the lesion is classified into different categories. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Bosniak classification of renal cysts'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major criteria for a single simple cyst on ultrasonography which, if present, allow it to be differentiated from a carcinoma or abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mass is round and sharply demarcated with smooth walls",
"     </li>",
"     <li>",
"      There are no echoes (anechoic) within the mass",
"     </li>",
"     <li>",
"      There is a strong posterior wall echo indicating good transmission through the cyst and enhanced transmission beyond the cyst",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No further evaluation is necessary if all of these criteria are satisfied, since the likelihood of a malignancy is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/15,17,35\">",
"     15,17,35",
"    </a>",
"    ]. The accuracy of ultrasonography in evaluating renal masses was illustrated in a retrospective study that assessed 260 lesions detected by intravenous urography in 242 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/17\">",
"     17",
"    </a>",
"    ]. The ultrasonographic diagnosis was confirmed by cyst puncture, surgery, or autopsy: 168 were benign cysts, and all were diagnosed correctly by ultrasonography. The remaining 92 lesions were renal carcinomas, 90 of which were diagnosed correctly by ultrasonography. Retrospective analysis revealed that the two missed cancers did not meet all three ultrasonographic criteria for a benign cyst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CT scan should be performed if the ultrasonogram is equivocal, if calcifications or septae are seen, or if multiple cysts are clustered in a pattern that could mask an underlying carcinoma. The CT images should be &le;5 mm in thickness and obtained before and after the intravenous administration of radiocontrast media.",
"   </p>",
"   <p>",
"    A simple cyst is considered to be present if, on CT scan (",
"    <a class=\"graphic graphic_table graphicRef67087 \" href=\"UTD.htm?14/61/15324\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2,3,15,16,35\">",
"     2,3,15,16,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cyst is sharply demarcated from the surrounding parenchyma and has a smooth, thin wall.",
"     </li>",
"     <li>",
"      Fluid within the cyst is homogeneous, with a density of less than 20 Hounsfield units (similar to water); however, higher values may be seen with a benign proteinaceous or hemorrhagic cyst.",
"     </li>",
"     <li>",
"      There is no enhancement of the mass following the administration of radiocontrast media, indicating the presence of an avascular lesion. Enhancement implies vascularity and is strongly suggestive of a malignant lesion even in the absence of irregular margins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings suggestive of malignancy are described above and include thickened irregular or smooth walls or septa and enhancement after contrast injection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77721 \" href=\"UTD.htm?36/42/37551\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Bosniak classification of renal cysts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, caution should be exercised when determining enhancement, since small cysts (less than 1 cm in diameter) may appear to enhance due to volume averaging from adjacent normal renal parenchyma. When this occurs or is suspected, ultrasonography or MRI is recommended to confirm the simple nature of the cyst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of clinical, radiographic, and others findings may confirm the presence of one of the rare complications associated with simple cysts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection &mdash; In the appropriate clinical setting, newly developed internal septations or layering material within an otherwise simple cyst may suggest the presence of infection. However, imaging studies are unreliable for diagnosing or excluding infection within a cyst. The clinical features of an infected simple renal cyst (such as fever and weight loss) are the same as those of renal abscess, which are discussed separately. Percutaneous aspirate with culture and gram stain may be diagnostic (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"       \"Renal and perinephric abscess\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypertension &mdash; The presence of hypertension in patients with simple cysts is most commonly the result of processes independent of the cyst, given that both simple cysts and hypertension are frequently observed among older individuals. Hypertension due to a simple cyst may be suspected in the patient with clinical features suggestive of secondary hypertension, such as spontaneous persistent hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemorrhage &mdash; Bleeding in a simple cyst is diagnosed by the characteristic imaging findings of high attenuation non-enhancing internal debris.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major concern with simple renal cysts is differentiating them from more serious disorders, such as polycystic kidney disease, complex cysts, and solid masses (such as a renal carcinoma or abscess). Ultrasonography, CT scanning,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI can be used to help establish the correct diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic kidney disease &mdash; The ability to distinguish simple renal cysts from polycystic kidney disease is easy in patients with overt polycystic disease. Affected patients may present with a positive family history, gross hematuria, cyst infection, flank pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency, and large kidneys with multiple bilateral cysts on ultrasonography or CT scanning.",
"      <br/>",
"      <br/>",
"      The diagnosis of polycystic kidney disease is somewhat more difficult to establish among patients with less severe disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in those who undergoing screening for the disorder. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"       \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized cystic disease &mdash; Localized cystic disease of the kidney is an uncommon benign condition that can be confused with polycystic kidney disease and simple renal cysts. In one series of 18 patients, the age at diagnosis ranged from 24 to 83 (average 54) and none had a family history of polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/19\">",
"       19",
"      </a>",
"      ]. Imaging studies revealed multiple cysts of various sizes separated by normal or atrophic parenchyma involving one kidney. Localized cystic disease is neither bilateral nor progressive, in contrast to polycystic kidney disease, and is often symptomatic (hematuria, flank pain, abdominal mass), in contrast to simple renal cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignancy &mdash; As mentioned above, CT scanning should be performed if ultrasonography is equivocal, if calcifications or septae are seen, or if multiple cysts are clustered in a pattern that could mask an underlying carcinoma.",
"      <br/>",
"      <br/>",
"      The following findings on CT scan (or MRI) are highly suggestive of a neoplastic lesion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77721 \" href=\"UTD.htm?36/42/37551\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67087 \" href=\"UTD.htm?14/61/15324\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/3,15,16,35\">",
"       3,15,16,35",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thickened, irregular walls",
"     </li>",
"     <li>",
"      Thickened or enhanced septae within the mass",
"     </li>",
"     <li>",
"      Enhancement of the lesion after intravenous contrast",
"     </li>",
"     <li>",
"      A multilocular mass",
"      <br/>",
"      <br/>",
"      In some cases, however, CT scanning is equivocal, being suggestive but not diagnostic of a simple cysts. This is discussed above. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Category IIF and III'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indeterminate lesions &mdash; The optimal approach to renal cystic lesions with indeterminate findings on ultrasonography and CT scanning is uncertain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Category IIF and III'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of simple cysts require no treatment. Therapy may rarely be required for symptoms, signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain &mdash; We treat pain associated with simple cysts conservatively, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or, if renal function is normal, an NSAID for three to five days. In patients with persistent pain, options include percutaneous aspiration, often with a sclerosing agent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/36-38\">",
"       36-38",
"      </a>",
"      ], or the cyst can be laparoscopically unroofed [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/39\">",
"       39",
"      </a>",
"      ]. Cyst sizes in patients who require intervention generally range from 5 to 20 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/36,39\">",
"       36,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infection &mdash; Infected cysts are frequently refractory to antimicrobial therapy, since most drugs (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) do not readily penetrate the cyst [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27704/abstract/40\">",
"       40",
"      </a>",
"      ]. Issues surrounding the treatment of infected simple cysts are similar to that associated with the treatment of infected cysts in patients with polycystic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4807?source=see_link\">",
"       \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension &mdash; The management of hypertension due to a simple cyst is similar to that of other forms of angiotensin-dependent hypertension. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cysts result from genetic or nongenetic processes, and occur in a variety of diseases in adults and children. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The evaluation of a solid renal mass is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bosniak classification of renal cysts",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To help diagnose and manage simple and complex renal cysts, the Bosniak renal cyst classification system was created. Based upon morphologic and enhancement characteristics with CT scanning, cystic renal masses are placed into one of five different categories (",
"      <a class=\"graphic graphic_table graphicRef67087 \" href=\"UTD.htm?14/61/15324\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bosniak classification of renal cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of true contrast enhancement of the lesion (a minimum increased attenuation of 10 to 15 Hounsfield units) is the most important characteristic separating categories III and IV; these are associated with malignancy in 40 percent or more of cases. By comparison, the categories I, II, and IIF are typically benign processes.",
"     </li>",
"     <li>",
"      The evaluation of renal cystic lesions is based upon initial classification according to the Bosniak CT system:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Further evaluation of Bosniak category I and II lesions is not required. If the clinician is unable to distinguish between a category II and IIF cyst, follow-up imaging should be performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Category I and II'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal approach to renal cystic lesions with indeterminate findings, usually Bosniak category IIF or III, is uncertain. With category IIF lesions, we recommend making every attempt to obtain prior studies for purposes of comparison. if such studies are unavailable, many radiologists would recommend an additional imaging study (typically a good quality contrast-enhanced MRI) for further characterization.",
"     </li>",
"     <li>",
"      With category III lesions, we also try to obtain prior studies for purposes of comparison. In the absence of prior studies or if symptomatic or associated with hematuria, we recommend further imaging evaluation with a good quality contrast-enhanced MRI. If the lesion is still indeterminate, we obtain a surgical consult. Such lesions are either removed or closely followed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Category IIF and III'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Category IV lesions require surgery, with approximately 85 to 100 percent being malignant. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Category IV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Simple renal cysts",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple renal cysts are observed frequently in normal kidneys. They are the most common renal masses, accounting for roughly 65 to 70 percent of cases. The prevalence of simple renal cysts varies with the population studied and the imaging modality utilized. These cysts most often occur in patients over the age of 50. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Simple cysts may be solitary, or multiple and bilateral. They typically produce no symptoms or signs. Rarely, however, they can be associated with rupture (hemorrhage), hematuria, pain, abdominal mass, infection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Simple renal cysts have characteristic changes on ultrasonography and computer tomography (CT). If basic ultrasonography criteria for a benign simple cyst are met, further study is not required. A CT scan should be performed if the ultrasonogram is equivocal, if calcifications or septae are seen, or if multiple cysts are clustered in a pattern that could mask an underlying carcinoma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major concern with simple renal cysts is differentiating them from more serious disorders, such as polycystic kidney disease, complex cysts, and solid masses (such as a renal carcinoma or abscess). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of simple cysts require no treatment. Therapy may rarely be required for symptoms, signs,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lippert, MC, Renal Cystic Disease, Adult and Pediatric Urology, 4th ed, Gillenwater, JY, Grayhack, JT, Howards, SS, Mitchell, ME (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, 2002, pp. 8589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/2\">",
"      Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. Urology 2005; 66:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/3\">",
"      Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol 2000; 175:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/4\">",
"      Harisinghani MG, Maher MM, Gervais DA, et al. Incidence of malignancy in complex cystic renal masses (Bosniak category III): should imaging-guided biopsy precede surgery? AJR Am J Roentgenol 2003; 180:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/5\">",
"      Richter F, Kasabian NG, Irwin RJ Jr, et al. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. Urology 2000; 55:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/6\">",
"      Israel GM, Bosniak MA. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am J Roentgenol 2003; 181:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/7\">",
"      Smith AD, Remer EM, Cox KL, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology 2012; 262:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/8\">",
"      Marotti M, Hricak H, Fritzsche P, et al. Complex and simple renal cysts: comparative evaluation with MR imaging. Radiology 1987; 162:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/9\">",
"      Balci NC, Semelka RC, Patt RH, et al. Complex renal cysts: findings on MR imaging. AJR Am J Roentgenol 1999; 172:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/10\">",
"      Curry NS, Bissada NK. Radiologic evaluation of small and indeterminant renal masses. Urol Clin North Am 1997; 24:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/11\">",
"      Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology 2004; 231:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/12\">",
"      Silverman SG, Gan YU, Mortele KJ, et al. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology 2006; 240:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/13\">",
"      Truong LD, Todd TD, Dhurandhar B, Ramzy I. Fine-needle aspiration of renal masses in adults: analysis of results and diagnostic problems in 108 cases. Diagn Cytopathol 1999; 20:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/14\">",
"      Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003; 169:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/15\">",
"      Bosniak MA. The small (less than or equal to 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991; 179:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/16\">",
"      Bosniak MA. The current radiological approach to renal cysts. Radiology 1986; 158:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/17\">",
"      Clayman RV, Surya V, Miller RP, et al. Pursuit of the renal mass. Is ultrasound enough? Am J Med 1984; 77:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/18\">",
"      Ravine D, Gibson RN, Donlan J, Sheffield LJ. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. Am J Kidney Dis 1993; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/19\">",
"      Slywotzky CM, Bosniak MA. Localized cystic disease of the kidney. AJR Am J Roentgenol 2001; 176:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/20\">",
"      Caglioti A, Esposito C, Fuiano G, et al. Prevalence of symptoms in patients with simple renal cysts. BMJ 1993; 306:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/21\">",
"      Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 2003; 58:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/22\">",
"      Terada N, Ichioka K, Matsuta Y, et al. The natural history of simple renal cysts. J Urol 2002; 167:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/23\">",
"      Terada N, Arai Y, Kinukawa N, Terai A. The 10-year natural history of simple renal cysts. Urology 2008; 71:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/24\">",
"      Rule AD, Sasiwimonphan K, Lieske JC, et al. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis 2012; 59:611.",
"     </a>",
"    </li>",
"    <li>",
"     Glassberg, KI. Renal Dysgenesis and cystic disease of the kidney. Campbell's Urology, 8th edition, Walsh, PC, Retik, AB, Vaughn, ED Jr, Wein, AJ (Eds), Saunders, Philadelphia, 2002, pp. 1925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/26\">",
"      Pedersen JF, Emamian SA, Nielsen MB. Significant association between simple renal cysts and arterial blood pressure. Br J Urol 1997; 79:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/27\">",
"      Ekart R, Hojs R, Krajnc I. [Simple renal cysts and hypertension]. Wien Klin Wochenschr 2001; 113 Suppl 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/28\">",
"      Chin HJ, Ro H, Lee HJ, et al. The clinical significances of simple renal cyst: Is it related to hypertension or renal dysfunction? Kidney Int 2006; 70:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/29\">",
"      Holmberg G, Hietala SO, Karp K, Ohberg L. Significance of simple renal cysts and percutaneous cyst puncture on renal function. Scand J Urol Nephrol 1994; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/30\">",
"      Al-Said J, Brumback MA, Moghazi S, et al. Reduced renal function in patients with simple renal cysts. Kidney Int 2004; 65:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/31\">",
"      Babka JC, Cohen MS, Sode J. Solitary intrarenal cyst causing hypertension. N Engl J Med 1974; 291:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/32\">",
"      Papanicolaou N, Pfister RC, Yoder IC. Spontaneous and traumatic rupture of renal cysts: diagnosis and outcome. Radiology 1986; 160:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/33\">",
"      L&uuml;scher TF, Wanner C, Siegenthaler W, Vetter W. Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol 1986; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/34\">",
"      Edwards EC, Farrar DJ. Pelvi-ureteric obstruction due to renal pelvis cyst. Eur Urol 1977; 3:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/35\">",
"      Curry NS. Small renal masses (lesions smaller than 3 cm): imaging evaluation and management. AJR Am J Roentgenol 1995; 164:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/36\">",
"      Fontana D, Porpiglia F, Morra I, Destefanis P. Treatment of simple renal cysts by percutaneous drainage with three repeated alcohol injection. Urology 1999; 53:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/37\">",
"      Akinci D, Akhan O, Ozmen M, et al. Long-term results of single-session percutaneous drainage and ethanol sclerotherapy in simple renal cysts. Eur J Radiol 2005; 54:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/38\">",
"      Zerem E, Imamov&iacute;c G, Omerov&iacute;c S. Symptomatic simple renal cyst: comparison of continuous negative-pressure catheter drainage and single-session alcohol sclerotherapy. AJR Am J Roentgenol 2008; 190:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/39\">",
"      Atug F, Burgess SV, Ruiz-Deya G, et al. Long-term durability of laparoscopic decortication of symptomatic renal cysts. Urology 2006; 68:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27704/abstract/40\">",
"      Muther RS, Bennett WM. Concentration of antibiotics in simple renal cysts. J Urol 1980; 124:596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1681 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27704=[""].join("\n");
var outline_f27_3_27704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BOSNIAK CLASSIFICATION OF RENAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT BY BOSNIAK CATEGORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Category I and II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Category IIF and III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Percutaneous needle biopsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Category IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SIMPLE RENAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bosniak classification of renal cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Simple renal cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1681\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1681|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/42/37551\" title=\"diagnostic image 1\">",
"      Cystic renal cell carcinoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1681|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/61/15324\" title=\"table 1\">",
"      Bosniak criteria renal cysts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4807?source=related_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27705="Overview of Guillain-Barré syndrome in children";
var content_f27_3_27705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Guillain-Barr&eacute; syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27705/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/3/27705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barr&eacute; syndrome (GBS), after the authors of early descriptions of the disease. Historically, GBS was considered a single disorder, but it is now known to be a heterogeneous syndrome with several variant forms. Most often, GBS presents as an acute monophasic paralyzing illness provoked by a preceding infection. In addition to the demyelinating form, which is the most common type, axonal forms of GBS are well-recognized.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, pathophysiology, clinical features, variants, diagnosis, pathology and prognosis of GBS in children. The treatment of GBS in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome is the most common cause of acute flaccid paralysis in healthy infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/1\">",
"     1",
"    </a>",
"    ]. It has an annual incidence of 0.6 to 2.4 cases per 100,000 population and occurs at all ages and in both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence is lower in children, 0.38 and 0.91 cases per 100,000 in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. GBS occurs rarely in children younger than two years of age, but can occur in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Males are affected approximately 1.5 times more often than females in all age groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome has occurred after patients have received vaccinations, but this danger may be overstated. As an example, in one report of all patients hospitalized for GBS in Finland between 1982 and 1986, measles-mumps-rubella vaccination did not cause an increase above the background incidence of GBS and no clustering of cases occurred at any time after administration of the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be a small increased risk of GBS following immunization with the quadrivalent meningococcal polysaccharide conjugate vaccine (MCV4). The possible association between MCV4 and GBS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H9#H9\">",
"     \"Meningococcal vaccines\", section on 'Possible association with Guillain-Barr&eacute; syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available evidence suggests no increased risk of GBS in children from the H1N1 influenza vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS is really a group of disorders rather than a single disease. It is now considered to be a syndrome with a number of variants. Peripheral nerve demyelination in the demyelinating form is believed to be immunologically mediated. A variety of clinical and experimental data have implicated both humoral factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/11\">",
"     11",
"    </a>",
"    ] and cell-mediated immune phenomena that damage myelin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the myelin-producing Schwann cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/12\">",
"     12",
"    </a>",
"    ]. There is no known genetic factor. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Variants of Guillain-Barr&eacute; syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately two-thirds of patients have a history of an antecedent respiratory tract or gastrointestinal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/13\">",
"     13",
"    </a>",
"    ]. A variety of infectious agents have been associated with GBS, although Campylobacter is the most frequent. Other organisms that commonly precede GBS include cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/14\">",
"     14",
"    </a>",
"    ], Epstein-Barr virus, Haemophilus influenzae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/15\">",
"     15",
"    </a>",
"    ] mycoplasma pneumoniae, the enteroviruses, hepatitis A and B, herpes simplex, and Chlamydophila (formerly Chlamydia) pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Campylobacter infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter infection is the most commonly identified precipitant of GBS and can be demonstrated in as many as 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/17\">",
"     17",
"    </a>",
"    ]. A case-control study involving 103 patients with the disease found that 26 percent of affected individuals had evidence of recent infection with C. jejuni compared with 2 percent of household and 1 percent of age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/18\">",
"     18",
"    </a>",
"    ]. Seventy percent of those infected with C. jejuni reported a diarrheal illness within 12 weeks before the onset of the neurologic illness. Campylobacter-associated GBS had a worse prognosis than other forms of the disease in this series, manifested by slower recovery and greater residual neurologic disability. The risk for developing GBS during the two months after having a symptomatic episode of C. jejuni infection is approximately 100-fold higher than the risk in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main lesions of GBS are acute inflammatory demyelinating polyradiculoneuropathy and, particularly in patients with Campylobacter-associated disease, acute axonal degeneration. These changes may be caused by cross-reacting antibodies to GM1 ganglioside (present in high concentrations in peripheral nerve myelin) formed in response to similar epitopes expressed by the infecting Campylobacter strain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In support of this concept, many of the Campylobacter strains associated with GBS belong to serotypes, notably certain O19 and O41 strains, which are seldom isolated from ordinary cases of enteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Polysaccharides of this serotype resemble human ganglioside found in human peripheral nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, mechanisms other than molecular mimicry may be associated with the production of antibodies to GM1 ganglioside [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/28\">",
"     28",
"    </a>",
"    ], and many patients with Campylobacter infection but no neurologic symptoms also form these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of antibodies to gangliosides, including N-acetylgalactosaminyl GD1a (GalNAc-GD1a), has been associated with a distinctive clinical pattern in GBS. In one study, patients with anti-GalNAc-GD1a antibodies were more likely to have no cranial nerve involvement (87 versus 38 percent), distal-dominant weakness (80 versus 25 percent), and no sensory disturbance (73 versus 22 percent) compared to those without antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/20\">",
"     20",
"    </a>",
"    ]. In another report, anti-GD1a antibodies were measured in patients with different subtypes of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/29\">",
"     29",
"    </a>",
"    ]. Antibodies were detected more frequently in acute motor axonal neuropathy, in which the axolemma and nodes of Ranvier (short intervals between successive segments of the myelin sheath of a nerve) are affected, than in acute inflammatory demyelinating polyneuropathy, in which a component of the Schwann cell is targeted.",
"   </p>",
"   <p>",
"    The GBS variant known as Miller Fisher syndrome, in which the cranial nerves are affected, also is associated with Campylobacter infection. Most of these patients have cross-reacting antibodies to GQ1b ganglioside, which is present in cranial nerve myelin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/27,28,30,31\">",
"     27,28,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute inflammatory demyelinating polyradiculopathy (AIDP), the most common form of GBS, two-thirds develop the neurologic symptoms two to four weeks after having what appears to be a benign febrile respiratory or gastrointestinal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/13,32\">",
"     13,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic presentation is fine paresthesias in the toes and fingertips followed by lower extremity symmetric weakness that may ascend over hours to days to involve the arms and, in severe cases, the muscles of respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The predominant symptoms of GBS at presentation in children are pain and gait difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/35\">",
"     35",
"    </a>",
"    ]. In preschool aged children, the most common symptoms are refusal to walk and pain in the legs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective series of 95 children with GBS, the most frequent initial symptoms were gait unsteadiness, neuropathic pain, and inability to walk, occurring in 45, 34, and 24 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/37\">",
"     37",
"    </a>",
"    ]. By the peak of the illness, the frequency of symptoms was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      79 percent had neuropathic pain",
"     </li>",
"     <li>",
"      60 percent could not walk",
"     </li>",
"     <li>",
"      51 percent had autonomic dysfunction",
"     </li>",
"     <li>",
"      46 percent had cranial nerve involvement",
"     </li>",
"     <li>",
"      24 percent could not use their arms",
"     </li>",
"     <li>",
"      13 percent required mechanical ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In those with cranial neuropathy, the facial nerve is most commonly affected, resulting in bilateral facial weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/37\">",
"     37",
"    </a>",
"    ]. Pain typically involves the back and the legs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autonomic dysfunction occurs in approximately one-half of children with GBS, and may include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A variety of cardiac dysrhythmias (asystole, bradycardia, persistent sinus tachycardia, and atrial and ventricular tachyarrhythmias)",
"     </li>",
"     <li>",
"      Orthostatic hypotension",
"     </li>",
"     <li>",
"      Transient or persistent hypertension",
"     </li>",
"     <li>",
"      Paralytic ileus",
"     </li>",
"     <li>",
"      Bladder dysfunction",
"     </li>",
"     <li>",
"      Abnormal sweating",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare patients have central nervous system involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination reveals symmetric weakness with diminished or absent reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Minimal loss of sensation occurs, despite paresthesias.",
"   </p>",
"   <p>",
"    Variable initial physical findings can render making an early diagnosis difficult. Examples of less common signs include predominant proximal weakness, hyperreflexia with extensor plantar response, and sphincter disturbances that raise concerns about a spinal cord lesion. Papilledema can occur with [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/41\">",
"     41",
"    </a>",
"    ] or without increased intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of patients reach the nadir of their function within two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/43\">",
"     43",
"    </a>",
"    ], followed by return of function occurring slowly over the course of weeks to months. A chronic (extending beyond two months), slowly progressive or relapsing inflammatory demyelinating polyneuropathy generally is considered a distinct entity from acute GBS.",
"   </p>",
"   <p>",
"    The clinical course of GBS in children is shorter than in adults and recovery is more complete [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In patients who did not require mechanical ventilation, the median time to recovery of independent walking was 43 to 52 days in children compared to 85 days in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VARIANTS OF GUILLAIN-BARR&Eacute; SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, GBS was considered a single disorder. It is now known to be a heterogeneous syndrome with several variant forms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In addition to the demyelinating form, which is the most common type, axonal forms of GBS are well recognized. Each variant of GBS has distinguishing clinical, pathophysiologic and pathologic features. The classic presentation of ascending paralysis is most common, but a number of atypical variants are recognized that present with local or regional involvement of particular muscle groups or nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Several have prominent cranial nerve involvement, including Miller Fisher syndrome, Bickerstaff brainstem encephalitis, polyneuritis cranialis, and pharyngeal-cervical-brachial weakness. Others include pure sensory neuropathy and acute pandysautonomia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute inflammatory demyelinating polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute inflammatory demyelinating polyneuropathy (AIDP) is the prototype of GBS, and is the most common form in North America, Europe and most of the developed world, where it accounts for about 85 to 90 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute motor axonal neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute motor axonal neuropathy (AMAN) is a pure motor form of GBS. This disorder is distinguished from AIDP by its involvement of predominantly motor nerves and an electrophysiologic pattern suggesting axonal damage. AMAN occurs mainly in northern China, but is also a common form of GBS in other locations, including Japan, Mexico, and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/54-60\">",
"     54-60",
"    </a>",
"    ]. It is more common in developing nations, has a seasonal incidence, and is associated with a preceding Campylobacter jejuni infection. In a series of 31 Japanese children with GBS classified by electrophysiologic criteria, AIDP, AMAN, and unclassified GBS were seen in 11, 15 and 5 children (35, 48 and 16 percent) respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presenting clinical features and recovery are similar to those of AIDP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/61\">",
"     61",
"    </a>",
"    ]. However, more patients have respiratory failure requiring assisted ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute motor-sensory axonal neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute motor-sensory axonal neuropathy (AMSAN) resembles the motor axonal variant but has more sensory symptoms. The course tends to be prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The pathology is predominantly axonal lesions of both motor and sensory nerve fibers. This form of GBS is recognized infrequently in children. The infrequent diagnosis may be caused in part by the difficulty of performing sensory testing in children and because electrophysiologic studies often are not done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Miller Fisher syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Miller Fisher syndrome (MFS) have external ophthalmoplegia, ataxia, and muscle weakness with areflexia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Incomplete forms include acute ophthalmoplegia without ataxia, and acute ataxic neuropathy without ophthalmoplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/52\">",
"     52",
"    </a>",
"    ]. Cerebrospinal fluid findings and electrophysiologic features are similar to those in acute inflammatory demyelinating polyneuropathy. Brainstem auditory evoked potentials demonstrate peripheral and central conduction defects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345309608\">",
"    <span class=\"h2\">",
"     Bickerstaff encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bickerstaff encephalitis is a brainstem encephalitis characterized by encephalopathy and hyperreflexia with features of Miller Fisher syndrome such as ophthalmoplegia and ataxia. It is not only clinically linked to Miller Fisher syndrome, but is associated with anti-GQ1b antibodies and can respond to IVIG and plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Some experts consider Miller Fisher syndrome Bickerstaff encephalitis, and pharyngeal-cervical-brachial weakness with anti-GQ1b antibodies to be overlapping expressions of the anti-GQ1b antibody syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Polyneuritis cranialis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with polyneuritis cranialis develop acute bilateral multiple cranial nerve involvement and severe peripheral sensory loss. They typically have bilateral facial weakness, dysphagia, and dysphonia with optic nerve sparing. Patients tend to be younger than those with other types. This variant is associated with preceding cytomegalovirus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebrospinal fluid findings and electrophysiologic features of polyneuritis cranialis are similar to those of AIDP. Contrast MRI shows enhancement of multiple cranial nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/70\">",
"     70",
"    </a>",
"    ]. More children with this variant require ventilator support than those with the more typical presentation of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/71\">",
"     71",
"    </a>",
"    ]. However, most recover fully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345309513\">",
"    <span class=\"h2\">",
"     Pharyngeal-cervical-brachial weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharyngeal-cervical-brachial variant of GBS is characterized by acute weakness of the oropharyngeal, neck, and shoulder muscles with swallowing dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Facial weakness may be present as well. Leg strength and leg reflexes are usually preserved. This form may overlap with Miller Fisher syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/73,75\">",
"     73,75",
"    </a>",
"    ]. It is thought to represent a localized form of axonal GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/52,72,73\">",
"     52,72,73",
"    </a>",
"    ]. Some patients with pharyngeal-cervical-brachial weakness have IgG autoantibodies to GT1a, GQ1b, or less often to GD1a.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345309167\">",
"    <span class=\"h2\">",
"     Other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of additional uncommon variants of GBS, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute pandysautonomia, which may respond to intravenous immune globulin [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/76\">",
"       76",
"      </a>",
"      ]. Symptoms include diarrhea, vomiting, dizziness, abdominal pain, ileus, orthostatic hypotension, urinary retention, pupillary abnormalities, an invariant heart rate, decreased sweating, salivation, and lacrimation. Reflexes are absent or diminished and sensory symptoms may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pure sensory GBS, with involvement of large sensory fibers leading to significant sensory ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/78\">",
"       78",
"      </a>",
"      ]. Reflexes are absent and there may be minor motor involvement. An association with antibodies to GD1b has been noted.",
"     </li>",
"     <li>",
"      Facial diplegia and distal limb paresthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/75\">",
"       75",
"      </a>",
"      ]. This is considered a variant of acute inflammatory demyelinating polyneuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sixth nerve palsy and distal paresthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilateral lumbar radiculopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paraparesis, with clinical and electrophysiological involvement limited to the legs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic studies are the most specific and sensitive tests for diagnosis of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .) They demonstrate a variety of abnormalities indicating evolving multifocal demyelination, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Partial motor conduction block",
"     </li>",
"     <li>",
"      Slowed nerve conduction velocities",
"     </li>",
"     <li>",
"      Abnormal temporal dispersion",
"     </li>",
"     <li>",
"      Prolonged distal latencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of conduction block usually is the earliest abnormality. Slowed nerve conduction velocities reflect the segmental demyelination. Absent H reflexes or abnormal prolonged F-waves indicate proximal nerve root involvement. A retrospective study assessed early electrophysiologic changes in 31 patients with GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/80\">",
"     80",
"    </a>",
"    ]. The H-reflex was the single most sensitive test for early GBS, being absent in 97 percent tested within seven days of the onset of neurologic symptoms. Testing for the H-reflex requires electrical stimulation of the sciatic nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link\">",
"     \"Nerve conduction studies: Late responses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A normal nerve conduction study occurring after several days of symptoms, particularly in the setting of severe weakness, renders the diagnosis of GBS unlikely. This finding should prompt a search for alternative explanations for the patient's illness.",
"   </p>",
"   <p>",
"    Electromyogram abnormalities typically are delayed for two to three weeks. The motor units show denervation potentials, reflecting secondary axonal degeneration.",
"   </p>",
"   <p>",
"    In the motor and motor-sensory variants of GBS, nerve conduction velocities are normal. In both forms, motor amplitudes in nerve conduction studies are less than 10 percent of normal, with severe denervation evident on follow-up needle examination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/81\">",
"     81",
"    </a>",
"    ]. In the motor-sensory variant, sensory amplitudes also are decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with GBS, lumbar puncture often reveals an elevated cerebrospinal fluid (CSF) protein with a normal CSF white blood cell count. This finding, known as albuminocytologic dissociation, is present in 50 to 66 percent of patients with GBS in the first week after the onset of symptoms and &ge;75 percent of patients in the third week [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/52,82,83\">",
"     52,82,83",
"    </a>",
"    ]. The elevated protein may be due to increased permeability of the blood-nerve-barrier at the level of the proximal nerve roots. A normal CSF protein is found in one-third to one-half of patients when tested earlier than one week after symptom onset.",
"   </p>",
"   <p>",
"    In a prospective series of 110 patients with GBS, initial CSF protein elevation varied from 45 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.45 to 2.0",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    in 73 percent of patients, but protein elevation as high as 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/82\">",
"     82",
"    </a>",
"    ]. As noted, the CSF cell count is typically normal, ie, &lt;5",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    However, a minority of patients with GBS have mildly elevated CSF cell counts. In the same series, the CSF cell count was &lt;5, 5 to 10, 11 to 30, and &gt;30",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in 87, 9, 2 and 2 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to patients with GBS who are not infected with human immunodeficiency virus (HIV), a CSF pleocytosis is common in patients who have GBS and concurrent HIV infection. Therefore, concurrent HIV infection or an alternative diagnosis (eg, Lyme disease or malignancy) should be considered in patients with a CSF cell count",
"    <span class=\"nowrap\">",
"     &gt;10/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In addition, other disorders, including inflammatory conditions (infectious or autoimmune) and demyelinating diseases, may be associated with leg weakness and CSF pleocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3392820\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal MRI with administration of gadolinium frequently shows enhancement of the spinal nerve roots and cauda equina during the first weeks after the onset of GBS in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. The enhancement may be diffuse or predominantly involve the ventral (anterior) nerve roots, and less often the dorsal (posterior) roots. In some cases, nerve root enhancement may be delayed and observed only on a repeat MRI.",
"   </p>",
"   <p>",
"    Evidence from uncontrolled retrospective studies suggests that the sensitivity of contrast-enhanced spinal MRI for the diagnosis of GBS is &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. Nevertheless, spinal nerve root enhancement is a nonspecific finding that can be seen in a variety of disorders including polyradiculopathy related to HIV or cytomegalovirus infection, chronic inflammatory demyelinating polyneuropathy, arachnoiditis, sarcoidosis, carcinomatous or lymphomatous meningitis, and certain metabolic diseases. Thus, the diagnosis of GBS cannot be made by MRI alone.",
"   </p>",
"   <p>",
"    Enhancement of the cranial nerves on contrast MRI has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/70,86\">",
"     70,86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Polyneuritis cranialis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the central nervous system, peripheral nerve, neuromuscular junction, and muscle may have features that initially resemble GBS (",
"    <a class=\"graphic graphic_table graphicRef80040 \" href=\"UTD.htm?32/45/33500\">",
"     table 1",
"    </a>",
"    ). However, consideration of the neurologic examination, clinical course, cerebrospinal fluid profile, and electrophysiologic findings usually establish the diagnosis of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic changes depend upon the form of GBS. In acute inflammatory demyelinating polyneuropathy and the Miller Fisher variant, a focal inflammatory response develops against myelin-producing Schwann cells or peripheral myelin. Infiltration of the epineural and endoneural small vessels (mostly veins) by lymphocytes and monocytes causes segmental myelin degeneration throughout the nerve. The inflammation is more intense at the junction of the dorsal and ventral roots.",
"   </p>",
"   <p>",
"    The demyelination blocks electrical conduction along the nerve. Axonal degeneration occurs as a secondary response; the extent relates to the intensity of the inflammatory response. All myelinated nerves (motor, sensory, cranial, sympathetic) can be affected. The breakdown of the blood-nerve barrier at the dural attachment allows transudation of plasma proteins into the cerebrospinal fluid.",
"   </p>",
"   <p>",
"    In the motor and motor sensory variants, the axon is affected without an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The primary immune process is directed at the nodes of Ranvier (short intervals between successive segments of the myelin sheath of a nerve). Macrophages infiltrate at the nodes and extend into the periaxonal spaces, resulting in axonal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/88\">",
"     88",
"    </a>",
"    ]. The motor nerves are involved at the ventral roots, peripheral nerve, and the preterminal intramuscular motor twigs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/89\">",
"     89",
"    </a>",
"    ]. In the motor sensory variant, sensory nerves also are affected.",
"   </p>",
"   <p>",
"    In a study of 29 children with GBS in China, electrophysiologic studies correlated with sural nerve biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients classified as having acute inflammatory demyelinating polyneuropathy based upon a physiologic pattern consistent with demyelination commonly had macrophage-mediated demyelination and lymphocytic infiltration. Sural nerves were normal or had few degenerating fibers without lymphocytic infiltration or complement activation in children with acute motor axonal neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main modalities of therapy for GBS include plasmapheresis and administration of intravenous immune globulin. Even before initiating specific therapy, common problems are when and whether to admit the patient to the intensive care unit (ICU) and when to consider mechanical ventilation. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of GBS in children does not correlate with long-term outcome. As many as 85 percent of children can be expected to have an excellent recovery. Approximately one-half of patients are ambulatory by six months, and 70 percent walk within a year after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/33,91\">",
"     33,91",
"    </a>",
"    ]. A better prognosis is associated with a gradual evolution of weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Mortality is approximately 3 to 4 percent, and usually is secondary to respiratory failure or cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/33,92\">",
"     33,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy with IVIG does not appear to improve the prognosis of GBS. In the only report since the introduction of this therapy, the long term outcome of GBS was evaluated in 31 children available for follow-up at an average age of 5.3 years after their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/93\">",
"     93",
"    </a>",
"    ]. Most were treated with IVIG (24 of 31 patients); seven with a milder presentation received supportive therapy alone. Mild weakness in at least one muscle group persisted in 23 percent of children, although this had minimal impact on function. Long term weakness was associated with age younger than nine years at onset and a rapid progression (&lt;10 days) to maximal weakness.",
"   </p>",
"   <p>",
"    In general, the prognosis in affected children is better than adults. In one study, pediatric patients with electrodiagnostic criteria associated with poor outcome in adults (low mean compound muscle action potential amplitude and fibrillation potentials) recovered without residual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an observational study of Japanese children with GBS, outcomes were generally favorable in both AIDP and AMAN subtypes, although delayed recovery was more frequent with AMAN [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27705/abstract/59\">",
"     59",
"    </a>",
"    ]. All 11 children with AIDP and 12 of 15 (80 percent) with AMAN regained the ability to walk independently at six months; 14 of 15 children (93 percent) with AMAN walked independently at two years. Differences in clinical recovery between children with AIDP and AMAN were not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/37/37457?source=see_link\">",
"       \"Patient information: Guillain-Barr&eacute; syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3392812\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guillain-Barr&eacute; syndrome (GBS) is the most common cause of acute flaccid paralysis in healthy infants and children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GBS is really a group of disorders rather than a single disease. Peripheral nerve demyelination in the demyelinating form is believed to be immunologically mediated. Approximately two-thirds of patients have a history of an antecedent respiratory tract or gastrointestinal infection. Campylobacter infection is the most commonly identified precipitant of GBS and can be demonstrated in as many as 30 percent of cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute inflammatory demyelinating polyradiculopathy (AIDP), the most common form of GBS, two-thirds develop the neurologic symptoms two to four weeks after having what appears to be a benign febrile respiratory or gastrointestinal infection. The predominant symptoms of GBS at presentation in children are pain and gait difficulty. Lower extremity symmetric weakness may ascend over hours to days to involve the arms and the muscles of respiration in severe cases. In those with cranial neuropathy, the facial nerve is most commonly affected, resulting in bilateral facial weakness. Autonomic dysfunction occurs in approximately one-half of children with GBS. Physical examination reveals symmetric weakness with diminished or absent reflexes. Most patients reach the nadir of their function within two to four weeks, followed by return of function occurring slowly over the course of weeks to months. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome is a heterogeneous syndrome with several variant forms. Each has distinguishing clinical, pathophysiologic and pathologic features. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Variants of Guillain-Barr&eacute; syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The classic presentation of ascending paralysis is most common with acute inflammatory demyelinating polyradiculopathy (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute inflammatory demyelinating polyneuropathy'",
"      </a>",
"      above) and the axonal forms (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute motor axonal neuropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute motor-sensory axonal neuropathy'",
"      </a>",
"      above) of GBS.",
"     </li>",
"     <li>",
"      Atypical variants present with local or regional involvement of particular muscle groups or nerves. Several have prominent cranial nerve involvement, including Miller Fisher syndrome (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Miller Fisher syndrome'",
"      </a>",
"      above), Bickerstaff brainstem encephalitis (see",
"      <a class=\"local\" href=\"#H345309608\">",
"       'Bickerstaff encephalitis'",
"      </a>",
"      above), polyneuritis cranialis (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Polyneuritis cranialis'",
"      </a>",
"      above), and pharyngeal-cervical-brachial weakness (see",
"      <a class=\"local\" href=\"#H345309513\">",
"       'Pharyngeal-cervical-brachial weakness'",
"      </a>",
"      above). Others include pure sensory neuropathy and acute pandysautonomia (see",
"      <a class=\"local\" href=\"#H345309167\">",
"       'Other variants'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrophysiologic studies are the most specific and sensitive tests for diagnosis of GBS. They demonstrate a variety of abnormalities indicating evolving multifocal demyelination, including partial motor conduction block, slowed nerve conduction velocities, abnormal temporal dispersion, and prolonged distal latencies. With lumbar puncture, characteristic cerebrospinal fluid findings include normal pressure, fewer than 10 cells (typically mononuclear), and an elevated protein concentration (&gt;45",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      Spinal MRI with administration of gadolinium frequently shows enhancement of the spinal nerve roots and cauda equina during the first weeks after the onset. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main modalities of therapy for GBS are plasmapheresis and intravenous immune globulin. Even before initiating specific therapy, common problems are when and whether to admit the patient to the intensive care unit and when to consider mechanical ventilation. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"       \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The severity of GBS in children does not correlate with long-term outcome. As many as 85 percent of children can be expected to have an excellent recovery. Approximately one-half of patients are ambulatory by six months, and 70 percent walk within a year after onset. Mortality is approximately 3 to 4 percent, and usually is secondary to respiratory failure or cardiac complications. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/1\">",
"      Jones HR Jr. Guillain-Barr&eacute; syndrome: perspectives with infants and children. Semin Pediatr Neurol 2000; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/2\">",
"      Beghi E, Kurland LT, Mulder DW, Wiederholt WC. Guillain-Barr&eacute; syndrome. Clinicoepidemiologic features and effect of influenza vaccine. Arch Neurol 1985; 42:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/3\">",
"      Rantala H, Uhari M, Niemel&auml; M. Occurrence, clinical manifestations, and prognosis of Guillain-Barr&eacute; syndrome. Arch Dis Child 1991; 66:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/4\">",
"      Oliv&eacute; JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barr&eacute; syndrome in children &lt;15 years of age in Latin America. J Infect Dis 1997; 175 Suppl 1:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/5\">",
"      Carroll JE, Jedziniak M, Guggenheim MA. Guillain-Barr&eacute; syndrome. Another cause of the \"floppy infant\". Am J Dis Child 1977; 131:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/6\">",
"      Buchwald B, de Baets M, Luijckx GJ, Toyka KV. Neonatal Guillain-Barr&eacute; syndrome: blocking antibodies transmitted from mother to child. Neurology 1999; 53:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/7\">",
"      Patja A, Paunio M, Kinnunen E, et al. Risk of Guillain-Barr&eacute; syndrome after measles-mumps-rubella vaccination. J Pediatr 2001; 138:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/8\">",
"      Verity C, Stellitano L, Winstone AM, et al. Guillain-Barr&eacute; syndrome and H1N1 influenza vaccine in UK children. Lancet 2011; 378:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/9\">",
"      Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:d5956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/10\">",
"      Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med 2011; 41:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/11\">",
"      Saida T, Saida K, Dorfman SH, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979; 204:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/12\">",
"      WAKSMAN BH, ADAMS RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 1955; 102:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/13\">",
"      Hahn AF. Guillain-Barr&eacute; syndrome. Lancet 1998; 352:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/14\">",
"      Steininger C, Popow-Kraupp T, Seiser A, et al. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis 2004; 189:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/15\">",
"      Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barr&eacute; syndrome. Brain 2000; 123 ( Pt 10):2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/16\">",
"      Schessl J, Luther B, Kirschner J, et al. Infections and vaccinations preceding childhood Guillain-Barr&eacute; syndrome: a prospective study. Eur J Pediatr 2006; 165:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/17\">",
"      Kuroki S, Saida T, Nukina M, et al. Campylobacter jejuni strains from patients with Guillain-Barr&eacute; syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993; 33:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/18\">",
"      Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barr&eacute; syndrome. N Engl J Med 1995; 333:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/19\">",
"      McCarthy N, Giesecke J. Incidence of Guillain-Barr&eacute; syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/20\">",
"      Hao Q, Saida T, Yoshino H, et al. Anti-GalNAc-GD1a antibody-associated Guillain-Barr&eacute; syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol 1999; 45:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/21\">",
"      von Wulffen H, Hartard C, Scharein E. Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barr&eacute; syndrome. J Infect Dis 1994; 170:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/22\">",
"      Aspinall GO, Fujimoto S, McDonald AG, et al. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barr&eacute; syndrome patients mimic human gangliosides in structure. Infect Immun 1994; 62:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/23\">",
"      Godschalk PC, Heikema AP, Gilbert M, et al. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. J Clin Invest 2004; 114:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/24\">",
"      Fujimoto S, Allos BM, Misawa N, et al. Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barr&eacute; syndrome. J Infect Dis 1997; 176:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/25\">",
"      Goddard EA, Lastovica AJ, Argent AC. Campylobacter 0:41 isolation in Guillain-Barr&eacute; syndrome. Arch Dis Child 1997; 76:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/26\">",
"      Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999; 122 ( Pt 3):449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/27\">",
"      Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr&eacute; syndrome: clinical and immunohistochemical studies. Neurology 1993; 43:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/28\">",
"      Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barr&eacute; or Miller Fisher syndrome. J Infect Dis 1997; 175:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/29\">",
"      Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr&eacute; syndrome. Ann Neurol 1999; 45:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/30\">",
"      Jacobs BC, Endtz H, van der Mech&eacute; FG, et al. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995; 37:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/31\">",
"      Chiba A, Kusunoki S, Obata H, et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997; 745:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/32\">",
"      Ropper AH. The Guillain-Barr&eacute; syndrome. N Engl J Med 1992; 326:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/33\">",
"      Evans OB, Vedanarayanan V. Guillain-Barr&eacute; syndrome. Pediatr Rev 1997; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/34\">",
"      Jones HR. Childhood Guillain-Barr&eacute; syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/35\">",
"      Pier DB, Hallbergson A, Peters JM. Guillain-Barr&eacute; syndrome in a child with pain: lessons learned from a late diagnosis. Acta Paediatr 2010; 99:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/36\">",
"      Roodbol J, de Wit MC, Walgaard C, et al. Recognizing Guillain-Barre syndrome in preschool children. Neurology 2011; 76:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/37\">",
"      Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barr&eacute; syndrome: a prospective multicentre study. Neuropediatrics 2007; 38:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/38\">",
"      Nguyen DK, Agenarioti-B&eacute;langer S, Vanasse M. Pain and the Guillain-Barr&eacute; syndrome in children under 6 years old. J Pediatr 1999; 134:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/39\">",
"      Hund EF, Borel CO, Cornblath DR, et al. Intensive management and treatment of severe Guillain-Barr&eacute; syndrome. Crit Care Med 1993; 21:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/40\">",
"      Maier H, Schmidbauer M, Pfausler B, et al. Central nervous system pathology in patients with the Guillain-Barr&eacute; syndrome. Brain 1997; 120 ( Pt 3):451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/41\">",
"      Morley JB, Reynolds EH. Papilloedema and the Landry-Guillain-Barr&eacute; syndrome. Case reports and a review. Brain 1966; 89:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/42\">",
"      Sullivan RL Jr, Reeves AG. Normal cerebrospinal fluid protein, increased intracranial pressure, and the Guillain-Barr&eacute; syndrome. Ann Neurol 1977; 1:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/43\">",
"      Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barr&eacute; syndrome. Ann Neurol 1990; 27 Suppl:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/44\">",
"      Kleyweg RP, van der Mech&eacute; FG, Loonen MC, et al. The natural history of the Guillain-Barr&eacute; syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry 1989; 52:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/45\">",
"      Cole GF, Matthew DJ. Prognosis in severe Guillain-Barr&eacute; syndrome. Arch Dis Child 1987; 62:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/46\">",
"      Briscoe DM, McMenamin JB, O'Donohoe NV. Prognosis in Guillain-Barr&eacute; syndrome. Arch Dis Child 1987; 62:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/47\">",
"      Wong V. A neurophysiological study in children with Miller Fisher syndrome and Guillain-Barre syndrome. Brain Dev 1997; 19:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/48\">",
"      Plasmapheresis and acute Guillain-Barr&eacute; syndrome. The Guillain-Barr&eacute; syndrome Study Group. Neurology 1985; 35:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/49\">",
"      Lamont PJ, Johnston HM, Berdoukas VA. Plasmapheresis in children with Guillain-Barr&eacute; syndrome. Neurology 1991; 41:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/50\">",
"      Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barr&eacute; syndrome. Ann Neurol 1990; 28:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/51\">",
"      Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barr&eacute; syndrome in children. Pediatr Neurol 2012; 47:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/52\">",
"      Yuki N, Hartung HP. Guillain-Barr&eacute; syndrome. N Engl J Med 2012; 366:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/53\">",
"      Arcila-Londono X, Lewis RA. Guillain-Barr&eacute; syndrome. Semin Neurol 2012; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/54\">",
"      McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/55\">",
"      Visser LH, Van der Mech&eacute; FG, Van Doorn PA, et al. Guillain-Barr&eacute; syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barr&eacute; Study Group. Brain 1995; 118 ( Pt 4):841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/56\">",
"      Ho TW, Mishu B, Li CY, et al. Guillain-Barr&eacute; syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 ( Pt 3):597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/57\">",
"      Reisin RC, Cers&oacute;simo R, Garc&iacute;a Alvarez M, et al. Acute \"axonal\" Guillain-Barr&eacute; syndrome in childhood. Muscle Nerve 1993; 16:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/58\">",
"      Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barr&eacute; syndrome: a reappraisal. Ann Neurol 1999; 46:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/59\">",
"      Nagasawa K, Kuwabara S, Misawa S, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barr&eacute; syndrome in Japan. Muscle Nerve 2006; 33:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/60\">",
"      Nachamkin I, Arzarte Barbosa P, Barbosa PA, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology 2007; 69:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/61\">",
"      Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology 1997; 48:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/62\">",
"      Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barr&eacute; polyneuropathy. Brain 1986; 109 ( Pt 6):1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/63\">",
"      Feasby TE, Hahn AF, Brown WF, et al. Severe axonal degeneration in acute Guillain-Barr&eacute; syndrome: evidence of two different mechanisms? J Neurol Sci 1993; 116:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/64\">",
"      FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/65\">",
"      Marks HG, Augustyn P, Allen RJ. Fisher's syndrome in children. Pediatrics 1977; 60:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/66\">",
"      Winer JB. Bickerstaff's encephalitis and the Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2001; 71:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/67\">",
"      Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/68\">",
"      Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/69\">",
"      Visser LH, van der Mech&eacute; FG, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barr&eacute; syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barr&eacute; Study Group. Neurology 1996; 47:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/70\">",
"      Fulbright RK, Erdum E, Sze G, Byrne T. Cranial nerve enhancement in the Guillain-Barr&eacute; syndrome. AJNR Am J Neuroradiol 1995; 16:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/71\">",
"      Polo A, Manganotti P, Zanette G, De Grandis D. Polyneuritis cranialis: clinical and electrophysiological findings. J Neurol Neurosurg Psychiatry 1992; 55:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/72\">",
"      Ropper AH. Unusual clinical variants and signs in Guillain-Barr&eacute; syndrome. Arch Neurol 1986; 43:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/73\">",
"      Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barr&eacute; syndrome. Arch Neurol 2007; 64:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/74\">",
"      Rousseff RT, Khuraibet AJ, Neubauer D. The \"Child in the Barrel syndrome\"--severe pharyngeal-cervical-brachial variant of Guillain-Barre Syndrome in a toddler. Neuropediatrics 2008; 39:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/75\">",
"      Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994; 51:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/76\">",
"      Nass R, Chutorian A. Dysaesthesias and dysautonomia: a self-limited syndrome of painful dysaesthesias and autonomic dysfunction in childhood. J Neurol Neurosurg Psychiatry 1982; 45:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/77\">",
"      Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/78\">",
"      Wicklein EM, Pfeiffer G, Yuki N, et al. Prominent sensory ataxia in Guillain-Barr&eacute; syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997; 151:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/79\">",
"      Ropper AH, Wijdicks EF, Shahani BT. Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barr&eacute; syndrome. Arch Neurol 1990; 47:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/80\">",
"      Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barr&eacute; syndrome. Arch Neurol 2001; 58:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/81\">",
"      McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991; 338:593.",
"     </a>",
"    </li>",
"    <li>",
"     Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barr&eacute; syndrome, FA Davis, Philadelphia 1991. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/83\">",
"      Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004; 148:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/84\">",
"      Co��kun A, Kumanda�� S, Pa&ccedil; A, et al. Childhood Guillain-Barr&eacute; syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 2003; 44:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/85\">",
"      Yikilmaz A, Doganay S, Gumus H, et al. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst 2010; 26:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/86\">",
"      Mulkey SB, Glasier CM, El-Nabbout B, et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barr&eacute; syndrome. Pediatr Neurol 2010; 43:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/87\">",
"      Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/88\">",
"      Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barr&eacute; syndrome. J Neurocytol 1996; 25:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/89\">",
"      Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/90\">",
"      Lu JL, Sheikh KA, Wu HS, et al. Physiologic-pathologic correlation in Guillain-Barr&eacute; syndrome in children. Neurology 2000; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/91\">",
"      Asbury AK. New concepts of Guillain-Barr&eacute; syndrome. J Child Neurol 2000; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/92\">",
"      Bradshaw DY, Jones HR Jr. Guillain-Barr&eacute; syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27705/abstract/93\">",
"      Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barr&eacute; syndrome. J Pediatr 2003; 142:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6235 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27705=[""].join("\n");
var outline_f27_3_27705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3392812\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VARIANTS OF GUILLAIN-BARR&Eacute; SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute inflammatory demyelinating polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute motor axonal neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute motor-sensory axonal neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Miller Fisher syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345309608\">",
"      Bickerstaff encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Polyneuritis cranialis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345309513\">",
"      Pharyngeal-cervical-brachial weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345309167\">",
"      Other variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3392820\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3392812\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/45/33500\" title=\"table 1\">",
"      Differential diagnosis of GBS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=related_link\">",
"      Nerve conduction studies: Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/37/37457?source=related_link\">",
"      Patient information: Guillain-Barr&eacute; syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27706="Diagnosis and classification of renal disease in systemic lupus erythematosus";
var content_f27_3_27706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and classification of renal disease in systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Andrew S Bomback, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/3/27706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/3/27706/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/3/27706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement is common in systemic lupus erythematosus (SLE). An abnormal urinalysis with or without an elevated plasma creatinine concentration is present in a large proportion of patients at the time of diagnosis of lupus nephritis, and may eventually develop in up to 75 percent of patients with a diagnosis of SLE. The most frequently observed abnormality in patients with lupus nephritis is proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings underestimate the true frequency of renal involvement as some patients may (rarely) have significant pathologic abnormalities without any clinical signs of renal involvement. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Silent lupus nephritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are several types of renal disease in SLE, most commonly immune complex-mediated glomerular disease, which are usually differentiated with a renal biopsy. In addition, renal diseases unrelated to lupus may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the epidemiology, pathogenesis, and classification of lupus nephritis will be presented here. The indications for renal biopsy and the approach to therapy in the different types of lupus nephritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of glomerular injury seen in systemic lupus erythematosus (SLE) (and in other immune complex-mediated glomerular diseases) is primarily related to the site of formation of the immune deposits, which are primarily due to anti-double stranded DNA antibodies (anti-dsDNA, or anti-DNA) directed against nucleosomes (a nucleosome consists of double stranded DNA wound around a histone octamer) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anti-DNA immune complex formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;These immune complexes are primarily composed of DNA and anti-DNA. However, immune complexes may also include aggregates composed of chromatin, C1q, laminin, Sm, La (SS-B), Ro (SS-A), ubiquitin, and ribosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. In addition, some anti-DNA may bind directly to components of the glomerular basement membrane and mesangium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/13\">",
"     13",
"    </a>",
"    ]. The immune deposits in lupus nephritis occur in the mesangium, subendothelial,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subepithelial compartments of the glomerulus.",
"   </p>",
"   <p>",
"    Deposits in the",
"    <strong>",
"     mesangium",
"    </strong>",
"    and",
"    <strong>",
"     subendothelial",
"    </strong>",
"    space are proximal to the glomerular basement membrane (GBM) and are therefore in communication with the vascular space. As a result, activation of complement (typically via the classical pathway) with the generation of the chemoattractants C3a and C5a results in the influx of neutrophils and mononuclear cells. These changes manifest histologically by a mesangial or focal or diffuse proliferative glomerulonephritis, and clinically by an active urine sediment (red cells, white cells, and cellular and granular casts), proteinuria, and often an acute decline in renal function.",
"   </p>",
"   <p>",
"    Although deposits in the",
"    <strong>",
"     subepithelial",
"    </strong>",
"    space can also activate complement, there is no influx of inflammatory cells, since the chemoattractants are separated from the circulation by the GBM. Thus, injury is limited to the glomerular epithelial cells and the primary clinical manifestation is proteinuria, which is often in the nephrotic range. Histologically, these patients most commonly have membranous nephropathy.",
"   </p>",
"   <p>",
"    The site of immune complex formation is related to the characteristics of both the antigen and antibody:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large intact immune complexes or anionic antigens (which cannot cross the anionic charge barrier in the glomerular capillary wall) are deposited in the mesangium and subendothelial space [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The degree of immune deposition then determines whether the patient develops mild disease limited to the mesangium or a more severe focal or diffuse proliferative glomerulonephritis. Experimental studies suggest that there are two primary mechanisms by which subepithelial deposits may form: a cationic antigen that can cross the GBM; and an autoantibody directed against epithelial cell antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=see_link\">",
"       \"Mechanisms of immune injury of the glomerulus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=see_link\">",
"       \"Pathogenesis of tissue injury in glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another important determinant of the site of immune complex formation may be related both to the charge of the antibody and to its antigen-binding region, since the antibody may bind to antigens at different sites in the glomerular capillary wall, thereby leading to different histologic and clinical manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/10,14,15\">",
"       10,14,15",
"      </a>",
"      ]. Some data suggest that intra-glomerular membrane-associated nucleosomes are targeted by anti-double stranded DNA autoantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all circulating anti-DNA antibodies in SLE are necessarily nephritogenic. One study, for example, compared 14 patients with both anti-DNA antibodies and active nephritis with 14 patients who had anti-DNA antibodies but no nephritis. The plasma anti-DNA antibodies in these clinically disparate groups were indistinguishable based upon isotype, charge, or cross-reactivity with histones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/17\">",
"     17",
"    </a>",
"    ]. Although not examined in the patients of this study, other studies have shown that anti-DNA antibodies capable of fixing complement are more nephritogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the nephrotoxicity of anti-DNA may not require immune complex formation. Anti-DNA antibodies appear to directly bind to human mesangial cells in vitro, and induce production of proinflammatory substances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, anti-DNA isolated during active lupus nephritis induced mesangial cell production of interleukin-1 (and other proinflammatory substances), which in turn increased synthesis of hyaluronan (an extracellular matrix component that accumulates during tissue injury, and recruits lymphocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/20\">",
"     20",
"    </a>",
"    ]. The plasma cells that secrete these autoantibodies have been located not just in the spleen and bone marrow but also in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the kidney may be a major site of autoreactive plasma cells in lupus nephritis.",
"   </p>",
"   <p>",
"    Some data suggest that autoantibodies against C1q, a complement component, may correlate with lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The mechanism of action may be initiated by the general deposition of immune complexes on the glomerular basement membrane, with C1q being fixed on these immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/25\">",
"     25",
"    </a>",
"    ]. Subsequent binding of anti-C1q antibodies to C1q activates complement, resulting in an influx of inflammatory cells.",
"   </p>",
"   <p>",
"    It has also been suggested that the IgG subclass may be a determinant of the inflammatory response that is induced by immune complex deposition. IgG1 and IgG3 fix complement, while IgG2 does so less avidly and IgG4 does not fix complement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, the latter two subclasses should lead to less inflammation. Consistent with this hypothesis are the observations that anti-DNA antibodies associated with diffuse proliferative glomerulonephritis tend to be IgG1 and IgG3 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/27\">",
"     27",
"    </a>",
"    ], while the immune deposits in membranous nephropathy are more likely to be IgG2 and IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/28\">",
"     28",
"    </a>",
"    ]. However, as noted above, the separation of the immune deposits from inflammatory cells in the circulation by the glomerular basement membrane is probably a more important reason why an inflammatory change is lacking in membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune complex deposition can activate other arms of the inflammatory response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upregulation and activation of adhesion molecules on endothelium can result in the recruitment of proinflammatory leukocytes and the initiation of autoimmune injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Activated glomerular cells, infiltrating macrophages, and T cells produce inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), tumor growth factor-beta, interferon-gamma, chemokines, and platelet derived growth factor. All of these inflammatory mediators have the potential to extend renal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/30-33\">",
"       30-33",
"      </a>",
"      ]. Activated platelets may also contribute to mesangial cell proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of genetic factors reportedly predispose to the development of SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased frequency and severity of lupus nephritis among African Americans has led to the examination of genetic factors that might predispose to lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. Polymorphisms in the immunoglobulin receptor alleles Fc-gamma-RIIa-H131, present on macrophages, have been associated with susceptibility to lupus nephritis in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/35,39\">",
"     35,39",
"    </a>",
"    ], although conflicting data exist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/36\">",
"     36",
"    </a>",
"    ]. Other studies have noted an association between polymorphisms in the Fc-gamma-RIIIa-F158 receptor allele and Fc-gamma-RIIIb and lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These polymorphisms result in alterations of the binding avidity of the receptors to their specific IgG subclasses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/37\">",
"     37",
"    </a>",
"    ]. It is hypothesized that this change permits the inappropriate deposition of circulating immune complexes in the kidney (and elsewhere) due to inadequate clearance by hepatic and splenic macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20101138\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with systemic lupus erythematosus (SLE) will have clinical evidence of renal disease, usually an abnormal urinalysis, at some point in the course of their disease. Clinically evident renal disease eventually occurs in approximately half of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. Study-to-study variations in prevalence estimates of lupus nephritis may be due in part to racial differences in disease prevalence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk of nephropathy, as well as varying definitions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease ascertainment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/43,47-49\">",
"     43,47-49",
"    </a>",
"    ]. The following summarizes the three largest available cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/41,44-46\">",
"     41,44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1000 consecutive patients from 12 clinical centers in Europe, 16 percent had nephropathy (defined as protein excretion &gt;0.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      [or 3+ on dipstick], cellular casts, or unexplained elevation of the serum creatinine by at least 0.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [75",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      at the time of SLE diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/41\">",
"       41",
"      </a>",
"      ]. During ten years of prospective follow-up, nephropathy developed in 28 percent, although it was unclear whether this represented only new cases or also included recurrent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of 1378 patients with SLE in the United States, renal disease (defined as protein excretion &gt;0.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      &ge;5 red blood cells per high power field, serum creatinine &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       &micro;mol/L],",
"      </span>",
"      or requiring dialysis or transplant), was present in 32 percent of patients within one year of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/45\">",
"       45",
"      </a>",
"      ]. At a mean disease duration of 9 years, 47 percent had protein excretion &gt;0.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and 6 and 4 percent had decreased GFR and end-stage renal disease, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using billing data from the United States Medicaid population (which mostly includes people in poverty and is enriched with ethnic and racial minorities), 144 individuals were identified as having SLE per 100,000 in the population over a five-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/49\">",
"       49",
"      </a>",
"      ]. A diagnosis of glomerulonephritis was made in 21.5 percent of these patients (31 cases of lupus nephritis per 100,000 individuals in the population). The true prevalence of lupus nephritis in this high-risk population is likely to be higher since follow-up was only five years and some patients may go undiagnosed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher incidence of lupus nephritis among patients with SLE in the United States as compared with Europe may in part reflect racial and ethnic differences. The incidence of lupus nephritis is higher in blacks (34 to 51 percent), Hispanics (31 to 43 percent), and Asians (33 to 55 percent) than it is in whites (14 to 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/42,48,49\">",
"     42,48,49",
"    </a>",
"    ]. Blacks and Hispanics also tend to present with more severe underlying histopathology, higher serum creatinine concentrations, and more proteinuria than whites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, blacks, Hispanics, and those living in poverty have a worse prognosis than whites and those with a higher socioeconomic status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Race and ethnicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most renal abnormalities emerge soon after diagnosis (commonly within the first 6 to 36 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/1,42,51\">",
"     1,42,51",
"    </a>",
"    ]. Although an elevated plasma creatinine concentration eventually develops in approximately 30 percent of all patients with SLE, evidence of decreased renal function is an uncommon manifestation within the first few years of diagnosis.",
"   </p>",
"   <p>",
"    The time course for the development of lupus nephritis varies with gender, age, and ethnicity. In a retrospective study in the United States, males, younger patients (eg, less than 33 years of age at diagnosis), and non-whites were at enhanced risk of developing nephritis earlier in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20101441\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with systemic lupus erythematosus (SLE), the presence of nephritis is suspected by an abnormal urinalysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevation of the serum creatinine, and the diagnosis is confirmed by histopathologic findings on renal biopsy. As noted above, some patients already have evidence for renal involvement at the time of SLE diagnosis. (See",
"    <a class=\"local\" href=\"#H20101138\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572998\">",
"    <span class=\"h2\">",
"     Detection of renal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE should undergo testing for renal involvement at regular intervals, including a urinalysis with examination of the urinary sediment, an estimation of urine protein excretion (usually a spot urine protein-to-creatinine ratio), and a serum creatinine and estimated glomerular filtration rate. Elevated anti-DNA titers and low complement (C3 and C4) levels often indicate active lupus, particularly lupus nephritis. The frequency of testing depends upon whether or not the patient has a previous history of renal involvement. In patients who have never been diagnosed with renal disease, this evaluation is typically performed by a rheumatologist. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Determination of disease activity and severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573005\">",
"    <span class=\"h2\">",
"     Diagnosis by kidney biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A kidney biopsy should be performed in most patients with SLE who develop evidence for renal involvement in order to establish the diagnosis and, as discussed below, the class of lupus nephritis. Determining the class of lupus nephritis is important for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment is guided by the histologic subtype (ie, the International Society of",
"      <span class=\"nowrap\">",
"       Nephrology/Renal",
"      </span>",
"      Pathology Society or World Health Organization class, the degree of activity and chronicity, and by complicating lesions such as interstitial nephritis and thrombotic microangiopathy).",
"     </li>",
"     <li>",
"      The clinical presentation may not accurately reflect the severity of the histologic findings. As an example, proliferative lupus may be present even if the patient has minimal proteinuria and a normal serum creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients with proteinuria less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and a",
"    <strong>",
"     bland",
"    </strong>",
"    urine sediment do not need to undergo a kidney biopsy unless worsening kidney function is noted during follow-up examinations. Such patients are unlikely to have a class of nephritis that warrants immunosuppressive therapy. These issues are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histopathology of lupus nephritis can be quite varied and, at times, lupus nephritis may be confused with other immune complex-mediated glomerulonephritides. However, some histopathologic features are highly characteristic of lupus nephritis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular deposits that stain dominantly for IgG and contain co-deposits of IgA, IgM ,C3, and C1q, the so-called \"full house\" immunofluorescence pattern. The full house immunofluorescence pattern may also be seen in patients with endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/52\">",
"       52",
"      </a>",
"      ], HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/53\">",
"       53",
"      </a>",
"      ], hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/54\">",
"       54",
"      </a>",
"      ], a portosystemic shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/55\">",
"       55",
"      </a>",
"      ], and poststreptococcal glomerulonephritis.",
"     </li>",
"     <li>",
"      Glomerular deposits simultaneously seen in the mesangial, subendothelial, and subepithelial locations.",
"     </li>",
"     <li>",
"      Extraglomerular immune type deposits within tubular basement membranes, the interstitium, and blood vessels.",
"     </li>",
"     <li>",
"      Tubuloreticular inclusions in the glomerular endothelial cells (",
"      <a class=\"graphic graphic_picture graphicRef79072 \" href=\"UTD.htm?33/37/34392\">",
"       picture 1",
"      </a>",
"      ). These inclusions are composed of ribonucleoprotein and membrane and their synthesis is stimulated by alpha-interferon [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/56\">",
"       56",
"      </a>",
"      ]. The only other circumstances in which these structures are prominent are in HIV nephropathy (associated with chronically high levels of circulating alpha-interferon) and treatment with alpha-interferon. However, patients with HIV nephropathy typically have collapsing focal segmental glomerulosclerosis rather than a proliferative glomerulonephritis with immune complex deposition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"       \"HIV-associated nephropathy (HIVAN)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with lupus nephritis have an immune complex-mediated glomerular disease. Over the last two decades, there have been several attempts by different societies, particularly the World Health Organization (WHO), to classify the different glomerulopathies associated with systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    Based upon clinicopathologic correlations, a lupus nephritis classification system was developed by a group of renal pathologists, nephrologists, and rheumatologists in 2004 (the International Society of Nephrology, or ISN, classification) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. This system appears to be associated with increased reproducibility compared with the modified 1982 WHO system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ISN classification system divides glomerular disorders associated with SLE into six different patterns (or classes) based on kidney biopsy histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Although the different classes tend to have distinct histologic, clinical, and prognostic characteristics, there is substantial overlap due in part to variations in sampling; ideally, the biopsy specimen should contain at least 25 glomeruli. In addition, a significant percentage of patients evolve from one class of lupus nephritis to another, sometimes after therapy and sometimes spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57,61-65\">",
"     57,61-65",
"    </a>",
"    ]. The evolution from one class of nephritis to another is not surprising, since the different histologic types represent nonspecific responses to immune complex deposition.",
"   </p>",
"   <p>",
"    Various serologic and urine markers have been examined as potential non-invasive determinants of histologic class [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/66\">",
"     66",
"    </a>",
"    ], including the combination of an elevated anti-DNA titer and low complement levels, anti-C1q antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/67\">",
"     67",
"    </a>",
"    ], tumor necrosis factor-like weak inducer of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/68\">",
"     68",
"    </a>",
"    ], and urinary neutrophil gelatinase-associated lipocalin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/69\">",
"     69",
"    </a>",
"    ]. However, no serum or urine marker of disease activity provides the degree of information that is gained by histopathology. Thus, classification of lupus nephritis is determined by kidney biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Minimal mesangial lupus nephritis (class I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This class of lupus nephritis is rarely, if ever, diagnosed because these patients typically have a normal urinalysis, no or minimal proteinuria, and a normal serum creatinine. As a result, a biopsy is not usually performed. Patients with class I disease have only mesangial immune deposits, identified by immunofluorescence alone, or both immunofluorescence and electron microscopy, but without light microscopic abnormalities. Minimal mesangial lupus nephritis (class I) represents the earliest and mildest form of glomerular involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mesangial proliferative lupus nephritis (class II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic changes with class II disease are manifested clinically by microscopic hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. Hypertension is uncommon, and the nephrotic syndrome and renal insufficiency are virtually never seen. Light microscopy with class II disease reveals mesangial hypercellularity (of any degree) or mesangial matrix expansion (",
"    <a class=\"graphic graphic_picture graphicRef80250 \" href=\"UTD.htm?27/46/28393\">",
"     picture 2",
"    </a>",
"    ). A few isolated subepithelial or subendothelial deposits may be seen on immunofluorescence or electron microscopy. Visible subendothelial deposits on light microscopy or any global or segmental glomerular scars (which are thought to be the result of previous endocapillary proliferation, necrosis, or crescents) are inconsistent with the diagnosis of class II lupus nephritis. Such findings would indicate either class III or IV disease. Extensive podocyte effacement with nephrotic syndrome can occasionally be seen, resembling minimal change disease. The renal prognosis is excellent and no specific therapy is indicated unless the patient progresses to more advanced disease. (See",
"    <a class=\"local\" href=\"#H5544576\">",
"     'Glomerular podocytopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Focal lupus nephritis (class III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with class III lupus nephritis usually have hematuria and proteinuria, and some patients will also have hypertension, a decreased glomerular filtration rate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrotic syndrome. Class III disease is defined histologically by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 50 percent of glomeruli are affected by light microscopy. If more than 50 percent were involved, then the disease would be defined as diffuse lupus nephritis (class IV). Although less than 50 percent of glomeruli are affected on light microscopy, immunofluorescence microscopy (for IgG and C3) reveals almost uniform involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Active or inactive endocapillary or extracapillary glomerulonephritis that is almost always segmental (ie, involves less than 50 percent of the glomerular tuft) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/58\">",
"       58",
"      </a>",
"      ]. Electron microscopy usually reveals immune deposits in the subendothelial space of the glomerular capillary wall as well as the mesangium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also subclasses of class III disease that are determined by the inflammatory activity (or chronicity) of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class III (A), which is class III disease with active lesions. This is also called focal proliferative lupus nephritis.",
"     </li>",
"     <li>",
"      Class III",
"      <span class=\"nowrap\">",
"       (A/C),",
"      </span>",
"      which is associated with active and chronic lesions. This is referred to as focal proliferative and sclerosing lupus nephritis.",
"     </li>",
"     <li>",
"      Class III (C), in which chronic inactive lesions with scarring are observed. This is also called focal sclerosing lupus nephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional histologic features include the proportion of glomeruli affected by fibrinoid necrosis and crescents, and the presence or absence of tubulointerstitial or vascular abnormalities.",
"   </p>",
"   <p>",
"    The renal prognosis in class III disease is variable, and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H10#H10\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Focal proliferative disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognosis in class III disease may be clouded by the inability to accurately determine the percent of glomeruli involved. This latter feature is due to the potential for sampling error induced by the relatively small number of glomeruli that are obtained on a typical percutaneous renal biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diffuse lupus nephritis (class IV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class IV lupus nephritis is the most common and most severe form of lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/71\">",
"     71",
"    </a>",
"    ]. Hematuria and proteinuria are present in virtually all patients with active class IV disease, and the nephrotic syndrome, hypertension, and reduced glomerular filtration rate are all frequently seen. Affected patients typically have significant hypocomplementemia (especially C3) and elevated anti-DNA levels, especially during active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Class IV lupus nephritis is defined histologically by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 50 percent of glomeruli are affected by light microscopy. If less than 50 percent were involved, then the disease would be defined as focal lupus nephritis (class III).",
"     </li>",
"     <li>",
"      Affected glomeruli display endocapillary with or without extracapillary glomerulonephritis. These lesions may be either segmental (class IV-S, involving less than 50 percent of the glomerular tuft) or global (class IV-G, involving more than 50 percent of the glomerular tuft) (",
"      <a class=\"graphic graphic_picture graphicRef60218 \" href=\"UTD.htm?25/53/26457\">",
"       picture 3",
"      </a>",
"      ). Mesangial abnormalities also may be observed. Electron microscopy reveals subendothelial deposits, at least during the active phase (",
"      <a class=\"graphic graphic_picture graphicRef79072 \" href=\"UTD.htm?33/37/34392\">",
"       picture 1",
"      </a>",
"      ). The presence of diffuse wire loop deposits, but with little or no glomerular proliferation, is also considered class IV disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also subclasses of class IV disease that are determined by whether affected glomeruli are involved segmentally (S) or globally (G), and by the inflammatory activity (or chronicity) of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class IV-S (A), which is class IV-S with active lesions. This is also called diffuse segmental proliferative nephritis.",
"     </li>",
"     <li>",
"      Class IV-G (A), which is class IV-G associated with active lesions. This is also referred to as diffuse global proliferative nephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A subset of patients with class IV-G (A) nephritis has severe segmental rather than true global glomerular lesions. However, because the segmental lesions in such patients involve more than 50 percent of affected glomerular tufts, they are classified as global (class IV-G) instead of segmental (class IV-S). Some investigators refer to this subgroup of lupus nephritis as class IV-Q disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with patients who have class IV-S and true global class IV-G disease, those with class IV-Q nephritis have a significantly lower remission rate and a significantly higher incidence of end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class IV-S",
"      <span class=\"nowrap\">",
"       (A/C),",
"      </span>",
"      which is associated with active and chronic lesions. This is also called diffuse segmental proliferative and sclerosing nephritis.",
"     </li>",
"     <li>",
"      Class IV-G",
"      <span class=\"nowrap\">",
"       (A/C),",
"      </span>",
"      which is class IV-G with active and chronic lesions. This is also called diffuse global proliferative and sclerosing nephritis.",
"     </li>",
"     <li>",
"      Class IV-S (C), which is associated with chronic inactive lesions with scars. This is also referred to as diffuse segmental sclerosing lupus nephritis.",
"     </li>",
"     <li>",
"      Class IV-G (C), which is class IV-G with chronic inactive lesions with scars. This is also called diffuse global sclerosing lupus nephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With active disease, proliferative and necrotizing lesions and crescent formation all may be present, affecting more than 50 percent of glomeruli on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The marked deposition of immunoglobulins (especially IgG) and complement (especially C3) in this setting (",
"    <a class=\"graphic graphic_picture graphicRef70781 \" href=\"UTD.htm?24/47/25328\">",
"     picture 4",
"    </a>",
"    ) results in thickening of the glomerular capillary wall (",
"    <a class=\"graphic graphic_picture graphicRef79072 \" href=\"UTD.htm?33/37/34392\">",
"     picture 1",
"    </a>",
"    ) and a pattern on light microscopy similar to that in membranoproliferative glomerulonephritis. These lesions are characterized by the marked influx of proinflammatory cells (monocytes,",
"    <span class=\"nowrap\">",
"     suppressor/cytotoxic",
"    </span>",
"    T cells), sometimes resulting in cellular crescents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Membranous lupus nephritis (class V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with class V lupus nephritis typically present with signs of the nephrotic syndrome, similar to that in idiopathic membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/5,62,76\">",
"     5,62,76",
"    </a>",
"    ]. Microscopic hematuria and hypertension also may be seen at presentation, and the plasma creatinine concentration is usually normal or only slightly elevated.",
"   </p>",
"   <p>",
"    Class V disease is characterized by diffuse thickening of the glomerular capillary wall on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef56549 \" href=\"UTD.htm?19/14/19689\">",
"     picture 5",
"    </a>",
"    ) and by subepithelial immune deposits (either global or segmental involvement) on immunofluorescence or electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef69348 \" href=\"UTD.htm?38/39/39543\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/58,76,77\">",
"     58,76,77",
"    </a>",
"    ]. Mesangial involvement may also be seen.",
"   </p>",
"   <p>",
"    Although subendothelial deposits can be seen by immunofluorescence or electron microscopy with class V disease alone, the presence of such deposits as detected by",
"    <strong>",
"     light",
"    </strong>",
"    microscopy warrants a combined diagnosis of class III and V disease, or of class IV and V disease. In this setting, the additional designation of class III or IV is based upon the distribution of the deposits.",
"   </p>",
"   <p>",
"    Membranous lupus nephritis may present with",
"    <strong>",
"     no other clinical or serologic manifestations of SLE",
"    </strong>",
"    (eg, complement levels may be normal and anti-DNA antibodies may not be detectable). There are, however, several findings on electron and immunofluorescence microscopy that, if present, strongly suggest underlying lupus rather than idiopathic membranous nephropathy. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Advanced sclerosing lupus nephritis (class VI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced sclerosing glomerulonephritis usually display slowly progressive renal dysfunction in association with proteinuria and a relatively bland urine sediment. Class VI disease is characterized by global sclerosis of more than 90 percent of glomeruli. It represents healing of prior inflammatory injury, as well as the advanced stage of chronic class III, IV, or V lupus nephritis. Active glomerulonephritis should not be observed. A retrospective study found that 4 percent of 169 renal biopsies from patients with lupus nephritis were classified with type VI disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/78\">",
"     78",
"    </a>",
"    ]. Identification of this lesion via renal biopsy is important since immunosuppressive therapy is unlikely to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573393\">",
"    <span class=\"h2\">",
"     Overlap of lupus and ANCA glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antineutrophil cytoplasmic antibodies (ANCA) are detected by indirect immunofluorescence in approximately 20 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/79\">",
"     79",
"    </a>",
"    ]. In addition, some patients with lupus nephritis have histologic features of a superimposed ANCA glomerulonephritis, including prominent necrosis and crescent formation with minimal or absent endocapillary proliferation or subendothelial deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. The prevalence of crescentic glomerulonephritis with ANCA glomerulonephritis was examined in a Chinese series of 327 patients with lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/81\">",
"     81",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 327 patients, 152 had class IV-G nephritis (46 percent).",
"     </li>",
"     <li>",
"      Of those with class IV-G nephritis, 33 had crescentic glomerulonephritis (22 percent of patients with class IV-G nephritis and 10 percent of the total).",
"     </li>",
"     <li>",
"      Of those with crescents, 10 had a positive ANCA (30 percent of patients with crescents and 3 percent of the total), including nine with a p-ANCA. Positive ANCA serologies were far less common in patients without crescents (2 percent).",
"     </li>",
"     <li>",
"      It was unclear whether or not the histologic features and clinical outcomes of patients with crescentic glomerulonephritis differed according to ANCA status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of patients with an apparent overlap of lupus and ANCA glomerulonephritis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2987984\">",
"    <span class=\"h2\">",
"     Renal limited lupus-like nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with renal disease have a histologic pattern of injury that is indistinguishable from lupus nephritis, but have no extrarenal symptoms, signs, or serologies suggestive of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/83-85\">",
"     83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was described in four women who presented with hematuria, proteinuria, and variable degrees of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/83\">",
"     83",
"    </a>",
"    ]. Renal biopsy in each patient revealed characteristic findings of lupus nephritis, including proliferative glomerulonephritis, a \"full house\" pattern of immune complex deposition as described above, and endothelial cell tubuloreticular inclusions. However, extrarenal signs of SLE were absent, ANA titers were negative or weakly positive, complement levels were normal, and anti-DNA titers were negative. Other causes of glomerulonephritis were also excluded. All were treated with glucocorticoids with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and, despite immunosuppression, three of the four patients required renal replacement therapy. (See",
"    <a class=\"local\" href=\"#H573005\">",
"     'Diagnosis by kidney biopsy'",
"    </a>",
"    above.) Some patients, mostly children with lesions of class V nephritis, initially presented with a \"lupus-like\" lesion and, after a variable period, developed clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serological features of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/84,86\">",
"     84,86",
"    </a>",
"    ]. In those cases, the glomerulonephritis simply heralds the arrival of overt SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the glomerulopathies, there are three other forms of lupus renal disease: tubulointerstitial nephritis; vascular disease; and renal disease infrequently associated with drug-induced lupus. The investigators responsible for the newest classification system of glomerular disease emphasize that the presence and severity of tubulointerstitial and vascular involvement should be noted in any biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tubulointerstitial nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubulointerstitial disease (interstitial infiltrate, tubular injury) with or without immune deposits along the tubular basement membrane is a common finding in lupus nephritis, almost always being seen with concurrent glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The severity of the tubulointerstitial involvement is an important prognostic sign, correlating positively with the presence of hypertension, an elevated plasma creatinine concentration, and a progressive clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In a Chinese study of 313 patients with lupus nephritis, for example, the presence of tubulointerstitial nephritis was significantly associated with a twofold higher risk of developing end-stage renal disease or a doubling of serum creatinine after controlling for other prognostic indicators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/90\">",
"     90",
"    </a>",
"    ]. As expected, both tubular atrophy and interstitial fibrosis were also associated with an increased risk. In contrast, the presence of tubular basement membrane deposits alone correlates with the serologic activity of the disease but not the prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a few cases, tubulointerstitial disease is the only manifestation of lupus nephritis. This possibility should be suspected when a patient with lupus presents with a rising plasma creatinine concentration and a urinalysis that is relatively normal or shows only a few red cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. These changes may be accompanied by signs of tubular dysfunction such as metabolic acidosis due to type 1 (distal) renal tubular acidosis, hyperkalemia due to impaired distal potassium secretion, or hypokalemia due to salt-wasting and secondary hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Autoantibodies directed against the acid-secreting intercalated cells in the collecting tubule may be responsible for the acid secretory defect in at least some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/95\">",
"     95",
"    </a>",
"    ]. A review of the mechanisms by which distal acid secretion can be reduced are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the renal vasculature is not uncommon in lupus nephritis and its presence can adversely affect the prognosis of the renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/78,96\">",
"     78,96",
"    </a>",
"    ]. The most frequent manifestations are immune complex deposition (which is typically associated with immune deposits in the glomeruli), immunoglobulin microvascular casts, a thrombotic microangiopathy leading to a syndrome similar to thrombotic thrombocytopenic purpura (TTP), and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/78,97,98\">",
"     78,97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular immune deposits are usually located beneath an intact endothelium. They typically produce no inflammation; however, fibrinoid necrosis with vascular narrowing can be seen in severe cases, often in association with moderate to severe hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/96\">",
"     96",
"    </a>",
"    ]. It is unclear in this setting if the hypertension contributes to the vascular injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if the vascular narrowing exacerbates the hypertension via activation of the renin-angiotensin system. Regardless of the pathogenesis, patients with necrotizing vasculopathy tend to have a worse renal prognosis than those with isolated glomerular disease.",
"   </p>",
"   <p>",
"    Rarely, patients with lupus nephritis develop renal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/99\">",
"     99",
"    </a>",
"    ]. These patients are typically nephrotic, and the pathogenesis and treatment of the renal vein thrombosis is similar to that in patients without lupus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5128268\">",
"    <span class=\"h3\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other patients present with glomerular and vascular thrombi, often in association with antiphospholipid antibodies such as the lupus anticoagulant (LA) and anticardiolipin antibodies, or antibodies against the von Willebrand factor convertase (ADAMTS13). The name LA refers to the ability of these antibodies to produce in vitro prolongation of the partial thromboplastin time. In vivo, however, antiphospholipid antibodies promote coagulation, leading to venous and arterial thromboses, thrombocytopenia, livedo reticularis, and, in women, frequent miscarriages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link\">",
"     \"Antiphospholipid syndrome and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Silent lupus nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in which renal biopsy was performed in patients without any clinical evidence of renal disease found mesangial, focal, or diffuse proliferative glomerulonephritis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/100-105\">",
"     100-105",
"    </a>",
"    ]. In one study, for example, kidney biopsy was offered to all patients with systemic lupus erythematosus (SLE) seen at a Japanese hospital over an 11-year period, whether or not clinical signs of renal disease were present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/105\">",
"     105",
"    </a>",
"    ]. Of the 195 patients who had adequate biopsies, 86 had no clinical renal involvement. Of these 86 patients without clinical renal disease, 13 (15 percent) had either class III or IV lupus nephritis, and 9 (10 percent) had class V (membranous) disease.",
"   </p>",
"   <p>",
"    The renal disease in patients with silent lupus nephritis often remains clinically silent and is associated with a benign renal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/101,102,105\">",
"     101,102,105",
"    </a>",
"    ]. This was illustrated in a series of 18 patients with silent lupus nephritis (half of whom were treated with glucocorticoids with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) seen at a single center [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/102\">",
"     102",
"    </a>",
"    ]. At a mean postbiopsy follow-up of 13 years, the mean serum creatinine was 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (71",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the mean creatinine clearance was 108",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and all had a normal urinalysis. However, 15 of these patients had only mesangial disease at initial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Drug-induced lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs can induce a lupus-like syndrome, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and, historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    . Renal involvement is uncommon but a proliferative glomerulonephritis or the nephrotic syndrome can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544576\">",
"    <span class=\"h2\">",
"     Glomerular podocytopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have demonstrated that a glomerular podocytopathy due to renal involvement in lupus can be associated with diffuse epithelial cell foot process effacement without immune complex deposition, which is the classic histologic finding of minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Such lesions have been termed \"lupus podocytopathy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/108\">",
"     108",
"    </a>",
"    ]. In a retrospective study of 470 renal biopsies from patients with SLE, biopsies with normal light microscopy and a histologic diagnosis of either focal segmental glomerulosclerosis or mesangial proliferative glomerulonephritis were further evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/106\">",
"     106",
"    </a>",
"    ]. The absence of endocapillary proliferation or necrosis or of electron dense glomerular basement membranes deposits was found in 18 such biopsies, of which eight were from patients with nephrotic-range proteinuria. At least 80 percent foot process effacement was observed in all but one of these eight patients.",
"   </p>",
"   <p>",
"    There is a possibility that these observations reflect the chance occurrence of SLE and either minimal change nephropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal segmental glomerulosclerosis. However, this should occur in less than 1 in 10,000 cases, a frequency that is much less than that observed in this study (7 of 470).",
"   </p>",
"   <p>",
"    Patients with a lupus-related podocytopathy often respond to a short course of high dose glucocorticoids similar to patients with isolated minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/3/27706/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24019259\">",
"    <span class=\"h2\">",
"     Collapsing glomerulosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collapsing glomerulosclerosis is characterized histologically by collapse of the glomerular capillary tuft with epithelial cell proliferation in the Bowman space and clinically by the nephrotic syndrome, renal impairment, and rapid progression to end-stage renal disease. Collapsing glomerulosclerosis is most often due to HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, collapsing glomerulosclerosis can also be seen in patients with lupus, usually during an active lupus flare. In addition, such patients may have concurrent lupus nephritis. These issues are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=see_link\">",
"       \"Patient information: Lupus and kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abnormal urinalysis (hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria) with or without an elevated plasma creatinine concentration is observed in up to 75 percent of patients with systemic lupus erythematosus (SLE). The most frequently observed abnormality is proteinuria. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been several attempts to classify the different glomerulopathies associated with lupus. A classification system formulated and published in 2004 divides the glomerular disorders into six different patterns or classes, based on kidney biopsy findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class I disease (minimal mesangial lupus nephritis) is characterized by mesangial immune deposits identified either by immunofluorescence alone, or by immunofluorescence and electron microscopy, but without light microscopic abnormalities. Patients with class I disease generally have a normal urinalysis and serum creatinine concentration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Minimal mesangial lupus nephritis (class I)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class II disease (mesangial proliferative lupus nephritis) is characterized by mesangial hypercellularity or mesangial matrix expansion on light microscopy. A few isolated subepithelial or subendothelial deposits may be seen on immunofluorescence or electron microscopy but no subendothelial deposits are visible on light microscopy. Patients present with microscopic hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria; hypertension is uncommon, and the nephrotic syndrome and renal insufficiency are virtually never seen. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mesangial proliferative lupus nephritis (class II)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class III disease (focal lupus nephritis) is defined by light microscopic appearance of endocapillary or extracapillary glomerulonephritis that involves fewer than 50 percent of glomeruli. Lesions are associated with focal subendothelial deposits on electron microscopy. Class III disease is further categorized depending on the chronicity of the lesions. Hematuria and proteinuria are seen in almost all patients, some of whom also have the nephrotic syndrome, hypertension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevated plasma creatinine concentration. Progressive renal dysfunction is uncommon when fewer than 25 percent of glomeruli are affected and glomeruli show only segmental areas of proliferation without necrosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Focal lupus nephritis (class III)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class IV (diffuse lupus nephritis) is defined by more than 50 percent of glomeruli displaying endocapillary with or without extracapillary glomerulonephritis. Class IV disease is further categorized into segmental (IV-S) and global (IV-G) depending on whether affected glomeruli have segmental or global lesions, respectively. Additional subclasses of class IV disease are categorized depending on the chronicity of the lesions. Hematuria and proteinuria are present in all patients with active disease, and nephrotic syndrome, hypertension, and renal insufficiency are frequently observed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diffuse lupus nephritis (class IV)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class V (membranous lupus nephritis) is characterized by diffuse thickening of the glomerular capillary wall on light microscopy and by subepithelial immune deposits on immunofluorescence or electron microscopy. Although subendothelial deposits can be seen by immunofluorescence or electron microscopy alone, the presence of such deposits as detected by",
"      <strong>",
"       light",
"      </strong>",
"      microscopy warrants a combined diagnosis of class",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      and V disease. Patients primarily present with nephrotic syndrome although hematuria and hypertension may be seen. The plasma creatinine concentration is usually normal or only slightly elevated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Membranous lupus nephritis (class V)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class VI disease (advanced sclerosing lupus nephritis) is characterized by global sclerosis involving more than 90 percent of glomeruli. It represents healing of prior inflammatory injury, as well as the advanced stage of chronic class III, IV, or V lupus nephritis. Patients display slowly progressive renal dysfunction in association with proteinuria and a relatively bland urine sediment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Advanced sclerosing lupus nephritis (class VI)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with lupus nephritis have histologic features of a superimposed ANCA-associated glomerulonephritis, including prominent necrosis and crescent formation with minimal or absent endocapillary proliferation or subendothelial deposits. (See",
"      <a class=\"local\" href=\"#H573393\">",
"       'Overlap of lupus and ANCA glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tubulointerstitial disease often occurs with concurrent glomerular disease and is occasionally the only manifestation of lupus nephritis. Patients present with a rising plasma creatinine concentration and a relatively bland urinalysis. Signs of tubular dysfunction may be present. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tubulointerstitial nephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular disease (such as thrombotic microangiopathy) is common and can adversely affect the prognosis of the renal disease. Patients may present with glomerular and vascular thrombi, often in association with antiphospholipid antibodies such as the lupus anticoagulant and anticardiolipin antibodies. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Silent lupus nephritis is defined as the presence of mesangial, focal, or diffuse proliferative glomerulonephritis in patients without clinical evidence of renal disease. Silent lupus nephritis is associated with a benign renal outcome. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Silent lupus nephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of drugs can induce a lupus-like syndrome, particularly those that are acetylated in the liver, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and less often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      . Renal involvement is uncommon but a proliferative glomerulonephritis or the nephrotic syndrome can occur. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Drug-induced lupus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A glomerular podocytopathy due to lupus may appear histologically similar to minimal change disease. (See",
"      <a class=\"local\" href=\"#H5544576\">",
"       'Glomerular podocytopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Clinical features of SLE. In: Textbook of Rheumatology, Kelley WN, et al (Eds), WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/2\">",
"      Baranowska-Daca E, Choi YJ, Barrios R, et al. Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum Pathol 2001; 32:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/3\">",
"      Ortega LM, Schultz DR, Lenz O, et al. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/4\">",
"      O'Flynn J, Flierman R, van der Pol P, et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol 2011; 49:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/5\">",
"      Kashgarian M. Lupus nephritis: lessons from the path lab. Kidney Int 1994; 45:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/6\">",
"      Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/7\">",
"      Hulsey M, Goldstein R, Scully L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/8\">",
"      Ben-Yehuda A, Rasooly L, Bar-Tana R, et al. The urine of SLE patients contains antibodies that bind to the laminin component of the extracellular matrix. J Autoimmun 1995; 8:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/9\">",
"      Akashi Y, Yoshizawa N. Participation of histones and ubiquitin in lupus nephritis. Nihon Jinzo Gakkai Shi 1995; 37:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/10\">",
"      Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/11\">",
"      Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/12\">",
"      Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 2012; 21:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/13\">",
"      Krishnan MR, Wang C, Marion TN. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int 2012; 82:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/14\">",
"      Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/15\">",
"      D'Andrea DM, Coupaye-Gerard B, Kleyman TR, et al. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996; 49:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/16\">",
"      Kalaaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/17\">",
"      Budhai L, Oh K, Davidson A. An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus. J Clin Invest 1996; 98:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/18\">",
"      Valle RR, Eaton RB, Schnneider G, Schur PH. Complement activation by antibodies to DNA in systemic lupus erythematosus measured by enzyme immunoassay. Clin Immunol Immunopathol 1985; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/19\">",
"      Du H, Chen M, Zhang Y, et al. Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis. Clin Exp Immunol 2006; 145:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/20\">",
"      Yung S, Tsang RC, Leung JK, Chan TM. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int 2006; 69:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/21\">",
"      Espeli M, B&ouml;kers S, Giannico G, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011; 22:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/22\">",
"      Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/23\">",
"      Horv&aacute;th L, Czirj&aacute;k L, Fekete B, et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/24\">",
"      Marto N, Bertolaccini ML, Calabuig E, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/25\">",
"      Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/26\">",
"      Schur PH. IgG subclasses--a review. Ann Allergy 1987; 58:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/27\">",
"      Schur PH, Monroe M, Rothfield N. The gammaG subclass of antinuclear and antinucleic acid antibodies. Arthritis Rheum 1972; 15:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/28\">",
"      Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 1970; 49:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/29\">",
"      Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/30\">",
"      Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/31\">",
"      Bergijk EC, de Heer E, Hoedemaeker PJ, Bruijn JA. A reappraisal of immune-mediated glomerulosclerosis. Kidney Int 1996; 49:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/32\">",
"      Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/33\">",
"      Vielhauer V, Anders HJ, Schl&ouml;ndorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol 2007; 27:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/34\">",
"      Delmas Y, Viallard JF, Solanilla A, et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney Int 2005; 68:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/35\">",
"      Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/36\">",
"      Karassa FB, Trikalinos TA, Ioannidis JP, FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002; 46:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/37\">",
"      Karassa FB, Trikalinos TA, Ioannidis JP, Fc gamma RIIIA-SLE meta-analysis investigators. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 2003; 63:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/38\">",
"      Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/39\">",
"      Gelmetti AP, Freitas AC, Woronik V, et al. Polymorphism of the FcgammaRIIalpha IgG receptor in patients with lupus nephritis and glomerulopathy. J Rheumatol 2006; 33:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/40\">",
"      Morel L. Genetics of human lupus nephritis. Semin Nephrol 2007; 27:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/41\">",
"      Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/42\">",
"      Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/43\">",
"      Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus 1997; 6:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/44\">",
"      Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/45\">",
"      Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006; 85:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/46\">",
"      To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005; 52:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/47\">",
"      Alarc&oacute;n GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/48\">",
"      Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/49\">",
"      Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013; 65:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/50\">",
"      Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/51\">",
"      Nossent HC, Henzen-Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990; 33:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/52\">",
"      Lee LC, Lam KK, Lee CT, et al. \"Full house\" proliferative glomerulonephritis: an unreported presentation of subacute infective endocarditis. J Nephrol 2007; 20:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/53\">",
"      Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with \"lupus-like\" features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/54\">",
"      Ramos-Casals M, Font J, Garc&iacute;a-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/55\">",
"      Smet AD, Kuypers D, Evenepoel P, et al. 'Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrol Dial Transplant 2001; 16:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/56\">",
"      Rich SA. De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon. J Clin Invest 1995; 95:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/57\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/58\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/59\">",
"      Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol 2006; 30:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/60\">",
"      Yokoyama H, Wada T, Hara A, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/61\">",
"      Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/62\">",
"      Appel GB, Silva FG, Pirani CL, et al. Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/63\">",
"      Lee HS, Mujais SK, Kasinath BS, et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/64\">",
"      Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/65\">",
"      Lu J, Tam LS, Lai FM, et al. Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 2011; 34:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/66\">",
"      Rovin BH, Zhang X. Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol 2009; 4:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/67\">",
"      Coremans IE, Spronk PE, Bootsma H, et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/68\">",
"      Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:R143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/69\">",
"      Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010; 49:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/70\">",
"      Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/71\">",
"      Schwartz MM, Lan SP, Bonsib SM, et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/72\">",
"      Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/73\">",
"      Schwartz MM, Korbet SM, Lewis EJ, Collaborative Study Group. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008; 23:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/74\">",
"      Akashi Y, Oshima S, Takeuchi A, et al. [Identification and analysis of immune cells infiltrating into the glomerulus and interstitium in lupus nephritis]. Nihon Rinsho Meneki Gakkai Kaishi 1995; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/75\">",
"      Davis JC, Tassiulas IO, Boumpas DT. Lupus nephritis. Curr Opin Rheumatol 1996; 8:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/76\">",
"      Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/77\">",
"      Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/78\">",
"      Descombes E, Droz D, Drouet L, et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/79\">",
"      Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003; 12:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/80\">",
"      Nasr SH, D'Agati VD, Park HR, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/81\">",
"      Yu F, Tan Y, Liu G, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/82\">",
"      Hervier B, Hamidou M, Haroche J, et al. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int 2012; 32:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/83\">",
"      Huerta A, Bomback AS, Liakopoulos V, et al. Renal-limited 'lupus-like' nephritis. Nephrol Dial Transplant 2012; 27:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/84\">",
"      Gianviti A, Barsotti P, Barbera V, et al. Delayed onset of systemic lupus erythematosus in patients with \"full-house\" nephropathy. Pediatr Nephrol 1999; 13:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/85\">",
"      Jones E, Magil A. Nonsystemic mesangiopathic glomerulonephritis with \"full house\" immunofluorescence. Pathological and clinical observation in five patients. Am J Clin Pathol 1982; 78:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/86\">",
"      Shearn MA, Hopper J Jr, Biava CG. Membranous lupus nephropathy initially seen as idiopathic membranous nephropathy. Possible diagnostic value of tubular reticular structures. Arch Intern Med 1980; 140:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/87\">",
"      Brentjens JR, Sepulveda M, Baliah T, et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus. Kidney Int 1975; 7:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/88\">",
"      Park MH, D'Agati V, Appel GB, Pirani CL. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/89\">",
"      Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/90\">",
"      Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/91\">",
"      Tron F, Ganeval D, Droz D. Immunologically-mediated acute renal failure of nonglomerular origin in the course of systemic lupus erythematosus [SLE]. Report of two cases. Am J Med 1979; 67:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/92\">",
"      Singh AK, Ucci A, Madias NE. Predominant tubulointerstitial lupus nephritis. Am J Kidney Dis 1996; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/93\">",
"      Kozeny GA, Barr W, Bansal VK, et al. Occurrence of renal tubular dysfunction in lupus nephritis. Arch Intern Med 1987; 147:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/94\">",
"      DeFronzo RA, Cooke CR, Goldberg M, et al. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med 1977; 86:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/95\">",
"      Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/96\">",
"      Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/97\">",
"      Abdellatif AA, Waris S, Lakhani A, et al. True vasculitis in lupus nephritis. Clin Nephrol 2010; 74:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/98\">",
"      Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 2009; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/99\">",
"      Gelfand J, Truong L, Stern L, et al. Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma infusion. Am J Kidney Dis 1985; 6:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/100\">",
"      Mahajan SK, Ord&oacute;&ntilde;ez NG, Feitelson PJ, et al. Lupus nephropathy without clinical renal involvement. Medicine (Baltimore) 1977; 56:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/101\">",
"      Leehey DJ, Katz AI, Azaran AH, et al. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1982; 2:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/102\">",
"      Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G, et al. Outcome of silent lupus nephritis. Semin Arthritis Rheum 1996; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/103\">",
"      Wada Y, Ito S, Ueno M, et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004; 98:c105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/104\">",
"      Zabaleta-Lanz ME, Mu&ntilde;oz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus 2006; 15:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/105\">",
"      Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 2012; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/106\">",
"      Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/107\">",
"      Dube GK, Markowitz GS, Radhakrishnan J, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol 2002; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/108\">",
"      Shea-Simonds P, Cairns TD, Roufosse C, et al. Lupus podocytopathy. Rheumatology (Oxford) 2009; 48:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/3/27706/abstract/109\">",
"      Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21:2028.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3056 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27706=[""].join("\n");
var outline_f27_3_27706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anti-DNA immune complex formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20101138\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20101441\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572998\">",
"      Detection of renal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H573005\">",
"      Diagnosis by kidney biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Minimal mesangial lupus nephritis (class I)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mesangial proliferative lupus nephritis (class II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Focal lupus nephritis (class III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diffuse lupus nephritis (class IV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Membranous lupus nephritis (class V)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Advanced sclerosing lupus nephritis (class VI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H573393\">",
"      Overlap of lupus and ANCA glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2987984\">",
"      Renal limited lupus-like nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tubulointerstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5128268\">",
"      - Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Silent lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5544576\">",
"      Glomerular podocytopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24019259\">",
"      Collapsing glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3056|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/37/34392\" title=\"picture 1\">",
"      SLE Tubuloreticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/46/28393\" title=\"picture 2\">",
"      SLE Mesangial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/53/26457\" title=\"picture 3\">",
"      SLE Proliferative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/47/25328\" title=\"picture 4\">",
"      SLE Proliferative IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/14/19689\" title=\"picture 5\">",
"      SLE Membranous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/39/39543\" title=\"picture 6\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=related_link\">",
"      Indications for renal biopsy in patients with lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=related_link\">",
"      Pathogenesis of tissue injury in glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_3_27707="Performance pharm stress tests";
var content_f27_3_27707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weighted mean sensitivities and specificities of pharmacologic stress tests derived from a meta-analysis of 82 studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pharmacologic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosine echocardiography",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosine SPECT MPI",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipyridamole echocardiography",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipyridamole SPECT MPI",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dobutamine echocardiography*",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dobutamine SPECT MPI",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SPECT: single photon emission computed tomography; MPI: myocardial perfusion imaging.",
"     <br>",
"      * One dobutamine echocardiographic study was not included because only multivessel disease was examined.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kim, C, Kwok, YS, Heagerty, P, Redberg, R, Am Heart J 2001; 142:934.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27707=[""].join("\n");
var outline_f27_3_27707=null;
var title_f27_3_27708="Altered oral physiology";
var content_f27_3_27708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions and therapies that can affect the physiology of the oral cavity in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic modification of the oral cavity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dental management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        Medications implicated in increased caries rate",
"       </td>",
"       <td>",
"        Modification of sucrose-containing-medication intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet disorders",
"       </td>",
"       <td>",
"        Oral mucosal and gingival bleeding",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophilia",
"       </td>",
"       <td>",
"        Oral and mucosal bleeding",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer and its treatment",
"       </td>",
"       <td>",
"        Oral bleeding; oral infection; impaired healing",
"       </td>",
"       <td>",
"        Treat according to protocols that account for impaired hematopoietic system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure disorders",
"       </td>",
"       <td>",
"        Decreased salivary flow; gingival overgrowth (diphenylhydantoin)",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene; surgical management of gingival conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ transplantation",
"       </td>",
"       <td>",
"        Gingival overgrowth secondary to cyclosporine and calcium channel blockers",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene; surgical management of gingival conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral, emotional, and psychiatric disorders treated with CNS medications",
"       </td>",
"       <td>",
"        Decreased salivary flow",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene; use of topical fluoride mouth rinses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure",
"       </td>",
"       <td>",
"        Uremic bone disease; impaired healing",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"       <td>",
"        Increased caries from sucrose-containing medications",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene; use of topical fluoride mouth rinses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulimia",
"       </td>",
"       <td>",
"        Erosion of teeth",
"       </td>",
"       <td>",
"        Restoration of teeth; use of topical fluorides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrostomy",
"       </td>",
"       <td>",
"        Increased calculus formation",
"       </td>",
"       <td>",
"        Maintenance of oral hygiene; increased frequency of calculus removal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright &copy; 2000 W.B. Saunders Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27708=[""].join("\n");
var outline_f27_3_27708=null;
var title_f27_3_27709="Sperm count at conception secondary hypogonadism";
var content_f27_3_27709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sperm count at conception in men with secondary hypogonadism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 273px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean sperm concentration at the time of first pregnancy (left) and subsequent pregnancies (right) in men with isolated hypogonadotropin hypogonadism (IHH, secondary hypogonadism). The horizontal bars represent the mean for each group and the shaded area represents the conventional range of normal. Pregnancy was often achieved at sperm counts well below normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Burris AS, Clark RV, Vantman DJ, Sherins RJ. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy.&nbsp;Fertil Steril 1988; 50:343.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27709=[""].join("\n");
var outline_f27_3_27709=null;
var title_f27_3_27710="Treatment of newly diagnosed WM";
var content_f27_3_27710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Approach to the treatment of newly diagnosed Waldenstr&ouml;m macroglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 267px; background-image: url(data:image/gif;base64,R0lGODlh9wELAcQAAP///wAAAIiIiLu7u0RERCIiIpmZmd3d3TMzM2ZmZhEREe7u7szMzFVVVXd3d6qqqiAgIEBAQFBQULCwsBAQEODg4HBwcMDAwKCgoNDQ0PDw8AAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD3AQsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDegGGh4iJiouMjY6PkJGSk5SHNZWYmZqbnJ2Nl56hoqOknDQBhEWop6lOqzOvra6sskGxMbe1RrkvvLpHvizBvzbDK8bEPcgpy8k+zSbQzi3SJdXTtLDYSNci3dvRl+BC3wDl4zDf5+jl6+jM4u/k2fK48VECBCcEAlELCgdGDECVL0e7HvzMDcC1MJA6GAMDFDghIIABERUvjsiI0SKABQkONWAwcESCBAAM/ygwRIABmYO9NBpwV6KgiYQb9b040BAAgn4jHjQzoFNESZs3YLogcAhBwJv9AvR0IbXkn4cQfVVEIKKAx40BuALwepGAUwAHGhiwCuDkggAPPqp9eY+aTJokkJLAKYNBAwULIwIFwLQZAY1GCRYtVpcFAZT/Bu+NOpVa5T5YScyUesLqAK+GAAgoUGDAA6aIRZM2jZpBgKcCX7kNIJkuvZSGLpu7ixaBIZSjDSHwDRfAgJUKLn62VPB4gOSEiQPXZ/a3iQFma/M1nusAcc4HFCwwDlqxwcYMvNYW8RitAgYHOBuYmFDqAgRqxYsWK8L7oQElqWRIPw0It8BmAaAkIP9tABQY1nhiZDbCSmF1tooCDnCnmgAJqPUVRgVw6KEBM7FnyFqyKVhYAhBG2BiF/JGgSIMohcfAaAfE108C+ijQj0r/ZHhUjz+KR0ADALh2I3X6DAQbbihBRQJbIzQgFmcOZAiAjxrq1Vg6JTgYQIsjFBaWAfEtNB9hUT3wU1cXFZBaAzpVhQoBWu433psizLQAnhshsOd6XUgoAowWovValwXEp8BueTX63G6uwSYnWw3k+RECmoKh1KHCnfBVieVZZBNn+cT31GuLDqmqNwfgZCp1/bw6ZXYlbEclnN4s9J6iAQ153m1ikslelBW5piZ9USnAXz4PTESCnL2WNID/by2FdEgCBnzHE7YMaGudi9qUsJluVnFZkWoNRpXaaO1COpxLWxrwVj8MJIedS/cRWmhj54rKWwNRYlTnQgWpK5665in8Zz9CHVBQQraW4BdgZUq2a4NIKuvmhP2s6+VtYJKQHoM3ISueRwQwuxsCOv3DZ5Ud20kCwQIIOkIBGUZcZQI5GxuGoStENNFmXrE7wodKe3MRSCK5tGCGaYlUxqfC8OafIRIfLFqTyF2EtHnOQWdmyLQCmwJP3BkirZmpnezVAA0MtplvXw9b7lKHUFtRWC7bN9x4Duhnsle+AXin2y6JacDfXsXKeIOHpPYF0TLAOw3WS2huhZJjEsF5/xDb/YK5C39jvPmXR6SumxMRoawK6z8IJXQtp9dzDO26k9xL7z/kDryovA9f8t7G622PEbtyhsfoyR8vA177BLCYDKXbIfwJC7aUlTWvLx3+CQ4g6ZP5Pw0UpfpKQB+F8zVYNXIV7lc/4AoPGF5D9ilsvL+/s0MeC94SlwXM5QXNG98M8vcRBTzqLSQxxHhCUjBgFO8J8KOB/7BQv5Rxh14omF8M+IeCDZJreiYIWAnuZQ3QaEsshSHAAkqyNc44SFADGchMFOebX/3NeiSA4AOsxAAGDoQfMqvgLi5YE+G4xCIFKBgDiJOf8eTMHC4M1UB8U4BwHUJiTsTib0IVH/8DgSZETQINAJmAtZMRqj314kfLtuaAMprKiWlKyURGg7jxiEkyWyOYTvB0Rjpyh4sugVwEe+iShJyRAX8yxKPMsUbfUcMEiErhisbDoAQ0Kk2jWUC/SkKnXgXNJwIYCFDstJDHuCYuXqqbAwQwy/JxZz4cgiM3mDgCJbVFHwEwX6CmFaeLdPKTdmockjjjSx5Rsi3I7El8HiA/InGwMcXy4ExidZYGdAwwBWkmAfK4Jhz943GNYtPNiqIqVVnFm0kCzECUmS+XlC+HhEHJdng2EDLJbgdEyyQK7pMhVB3sJBhJQEmopRBxJYgtNmsLt6TlJQEQcYgIiIuTvMIAXVr/0JLck9ZnFFKCqiHgItCSlkGrtQp4yUekE1mpQjpauWpWjH7YPITQ4KbOsWjkMAVZE3nIuUedyAmhPeVVxhyAEqsw9DDykxMiSrMKhCJRXChxwHMqmRSSqfBW/HqTTKUSygWEiJQ1G8ApEyM+q5zEl6U0mQMbGDonTUyJARSgCuAKzNfBS2arRNjBrIIAlBSHryQ91QASwJW3oMiK1rxCG9WzjwriBJ7KCmcAGgfMshQVTmUN0TqnVIBf9ZNjSYpoYesZGxFYVQB+8okUF/VPHWyvpGIy31hbyZIZouJkiaPciSCqONeiRFsFuN6W0CcWJ5UJr6LjJVjC8sTK/FAj/4WD0G5jdxZtgZG6iR3sSshyH4k0h0JcTUIHc2VZoBjSJn9DQCKF81mfllcBoh1BIEUAMxGUt1HEEVJTAvJDhVZVnwLYWhRjF6XaKk96YyCYp6RrAxJOiXq20SsY/qFADV0OpFsozFk+DOIc2I4FJtQeha/ggBj1D8PR1XD0rLFiQkBSGTWeMQpuG731yoIADuwwhIesYxTKuAkbTHFSLqNkIx/ZMt87A1EA8DH2WM7JWAaD/0SohMPISMjmKHEJGAiAwonAlhLxL34t4xlfNPkSTL5FBrNMZGa4bSFz9vB1eMHlzsCGT1Mcl3O6CIOZrSgl8lVJf8Qj1CfvDghwzP/jDra8mDejwAFFie/tSqo/hdyUeI5e4WZ98iuxFmcm0mpBm0sI4y/vGcdilhFKH5XnJPNZuSjo1lkE06cM+ZJLLXYBr1WzgPDE5S8IoKiCUk3n30E6SpLWAaVrQJRVAjG1LuEUCzgEvk+HQ69fJcFPgiQACJqDAPqAGbPJLALXvGU5Etnic0B4yHmLZnISGWOFCNNb4TKIMzH0LSIVIu9fOVuA4V7aRSolFTsK6ozCxSEqtpYAOyZAq4ag934IUJnSQdDdehYNQMJz5ctqiS8X78qycrw00kHbhgYaiFcU4CAhha03/6FhgFWzEomrpo8lDUkDpgJfscTyEEApDc7/c+NtGutVoHlpwBCnPknaKCBanvvIZucjsWUWlzutrCA+XfkrNO8ommX9iQAAok6yFkCU6Rs1PFmZzzpfkgRQVzg0SdofuMhPZ3GnkXuW5I24mCAkV04qewScmCe1eGaTYQ9Q2lNanVS50c2mCg5AYzkz5eaUcV9IcnGzpSIZ8ErFxSw4327WVBKkUefUTJpNAF+dZH3tAUlIlePa8EWpIKChMkG+ZhkkLVkkJALIOipP2iHKrFqiFzYugtK8W6RyCKn1WSyyDAwigh/Y7sIoQd69ge8B0HS4VUUE90v1ONt7hUU1gVnHB3OfKIF8YwVwccZEkCnJowU2ddMnzLY8/6G2Py+3WOpnFQnhJL73GgxlM0/VfsciLD4VdMFEdLZndIuBfQSSdBrRe08CanSWcBNSalfnNPmyAMq3dijhQNV1Wm4ldgfGWuKTNwoRWsnHeqLldqJ0VqtQWN5nXOD3aCNAgpAiPoyldY+lJ60lYcOEd4mna7CBE8eRGsDmYpiWX7kCFKFkbKIGIZhHgJmXA5FGVjrDVupUEg6DWTbDhmqlDyRHgQylSYNhE76kbRuhg+UWOqilLE0nI7EWJpOkVdqFGMqnLGWmUgPwXzEYfdBXYOHVK/xmPXDnNpQxiTLEXQERUUileYHoNF82aBbxX/6GIkv3GvmSIDCyacYRLP990xbqZxzjRW+h5BqpETtvMy5RV4SIkF6A+InYc4ClqID9YC03Jzc2815WI4epMX0ogwgEZiBBRBwhYlG9hDi9dwi4FmYFGAdmlXi2wHKEkFG2JY5NUClX8I3kyBjd6AbaqF7mOGM+FgWx44vcwBLl2I7DM49F5nT6KA85MoTw0I8iOIYEuWPxOA2FwyWeaJBH8A+wYWnbto01+AJ9RoQOyTzfIJFDYGF3948VZo8hRwbh4R4Qwm0DmZEvAHlC4QJT1lphmDkUKYklsEHz45HeQGFGQxFfwRHCdmtF02owgBM4iZFiiBBIp3gVWZNAuRM9gWnTpTODpnErAJUd8SD/4QEgBlcaTcdjJMAjljNsk7gUt4gKMRkDF1lrWoFrRcmPIwkWYkEWCNSUL+YERCmS3waSL9Ae88Q/efaWNsgCF9MQ+IhtPpEhV9gL13aHGbJ2pRUsE9GVwNgnfwF/+9daJfUdCxEe4wFvZjmAfbItP/cg91aYiTFw2fgghSQdeQNvJFI5GDdqv4hwuZEo5MEcq3EaTPM1FVE1DxIg22JxrnmboSEjxKEcnDcWtfIaOXRH4BUWJwKLJ4IgRMGaovUPhvd7CakCcJQcjsQ44vJdXaRzv2FxC1Ib2AF5NnhFX3N/sTAQcQGENZGBBlOEYgE0apOXR5kOH6IruWAlkpgl/4dSjJ+pAn5iTsmBiHoxT6gFP9P0TjXyHglzEQwkK9npj1k2fh6GIYwiIjPxmmk2GggDeK4neyqoE9DBQFzSPCEzESn6KKLlTgwiTs+0dl/JFUTZJK+xJmepn/spA8m5FwryGvtUUAvBWveEChJmIzYBKCmUIBRhe+7XZk+SP3E1n/XJLgmAXwHxFuMhmSBpAJVJJv5pAg/oKy7xKgECmoj2RTYhJ0K1oC0VU+YHN06FCO1nR1yDE8FhmS13GxpKQ63yeo5yhDnhWglolt5SEHrKKq4IPnrUqAcQo8y5CkI1UpxhVxTiMuqkKhx2Uh+pkjTAU1clmvIxVQuFpzZxLf/Wo3HpWRtFZzDueXh8iKX7UZ8LAELWmJ8YKpAlAJb7oDH/mVZVVnr3pkcnwDNU9hpvagCIhZlAKBVJ6Fin5YT1CR1l0inY+qe0+ZfpEjKvFy+7WXQtslA9w6xisa3Gui6utibq2h69aRWIhSWSEhcOQB8nt5wEhgCTFH6TOZTtFVvRGhc0qCHWeqs3A12DeaiGqW2JSQLRgm5R2m6jhofiZnhgKqomkQjK8YqTyDTISDd2Ixxm2YvTFTnNKp39FRvCsYlamW/2wkU11DXEeTQDsoq96quJkWZj0zSGmqXDSBBug4oroVAQdzdytnLwNhER4Rs88Qrx9UR3NomkgRv/FkExi8JCofqjOuBR/KBgx8U1BUaeXJOKPDI5KMA25vBFpSmVs3hhkBRF1sC2mmYx/aqni+GVPgA6rPgDHPkMCal8bfCXwtZp2vmv9SCg/qqx0paUSvC3sKaXpak6cEC4LWCxi8u4BzmbXPsFN0Zikqtjbrm53Nq5XQBklMsFo0uQq0u6emsFU1asXpYFrVsGcgpQYIaQiPsFkPs+u3sCfBJJpDmVhVaHBtItDKBoJvmHGERhZGZmZbZM0vIPbKoDN1lJt2tbl1F7h/uPP9QAIYhiq0CBrwaY4gtpeKmzPsoCwHphKBMrPdgPDyu+KMOYDeIsysarVMCP5sav2RYV/6c2e0iAk9lrENs7k5xruiZwr2nKcTGwKyLUu47oA0Upjtcgpgrgp0qJSrO6ESOnrv6HsEiRcmOxmb6HU7dhhOOGIXv4RBKrbiXVFLlKRcL7KGWDnANSEOICohYxnD9UadBpWsnZMiwxc7nXb9I6SGICNGl0P6V7lG50Aic4JTdXHVB6nmfEgL/hTD6VxRO3c3yElTJMJTWcR/1ExNZjxOZwnNQZtYQBGkQMEDVslAc3Pf0Jq1xBpSTweG/Ehe43FgpgeWLBvLMAqMFXE1KXyGRmdVg3EUGqKA/AntzRIlwCJAwZmG2Bo0DxogoKxGFXL1T2KBK7Q8qZdpTRTswqpf/Gur517G9Cc8IDmhJGoqOxkierZhNcfCnjq6TfpFawt60P+p61ilBWpQ+kvIMhI8r4MmrONMqc4YN9+8St3AIYrMHbwVjj0cHTon8hzJ6MCoDuBctTgDUaOnzlhiHGZwDId4hwY1IXoVU+YiuOeqhr5zadyrEUBcTGJakLuAr8YH2G1Uq0NB0Gk7FZlk3ilxryHCv6yqotccs6kcumqCER2Kzn18O3AM/FCBCL0s/+l6lE+iMwlYb+3A8aTccN6QLtu4X9IZ+xHGx73DJ9TLHZ1ile2nfh67spXJtSbIKGZxEpqHzT+iGeUykOc8mpUhz3Shhasq3PioYI9a4EKnn/OEhSn+FDGrjKOdvKUbzAShcrx5HMD8OrBAODBGF0TKsvdcXLqfWGcDLUE20xHY0f/keMJLXUgIJYHp1U6JiSCkyreNo2PDtVsigRtPh2tui+s1e3u9h37zjONfYXZ8aHRD2Aovg4NSWaN1zYtDExbmOzPQxxL6TP0Le0JO1/Acd3K2u25+XEOTmZWMUTVayvhdFFjPhbRTupYZEct710jWlUazFeGK3YUSIUDbHX9TG1m4HZ4IXcrqeLuqu5WbCOW1C7v8Bh0i3NeXCRNJlXf91j29kKMP3d0b0HXigMuYsDrws81i2P4e3eofsO7Q3ev8u69c0O783e+Z086907//MNZ6nglmWY3lBWAxOTvjTA3dnNjaT72vFN3/o44FhQwTmg4OQdDaWQ4Rq+4ZSwYo+0xtE5nGgcxy7rcNFMB5PlYHWnKIs1SLNUWqR5Q76lQ5N0RVIRaMFUmpu12bG5JNSpH5IsywPCxXgSHGFBHHFhxRUXnGAMGsNhCPZ6CFTJ4CqWB92grAwCLy9KGMb8zJfYdxe6B1iD0HuRCAOAyhKjh6Dnev0Qe9Bhhr0EP5W8Mtl54Lwyh0ytX6+hKjiiI79EGDVDeH24ejnSScAU5lstB0JZ3S8ANdbxUvw81W1Xp5VzFTklQR7E4mzCVDb4GA7FfQYTLb3izo220H16ov89lVI1CS6bTtCRKCsSWIGEEesrdeoFWQeLrgXQILABjaxS7WHZB9eWfhtdzV59FxillUhwmBxrpWfxkV/wMxqIGMtrR8kS6KSAhQISdtXKLol2HjHs6YaKhckg7OBV/jw7QY29viam7dwEJ9zgeAcCLow+YXtWE7RfaThkVek/RBJh8w8GElTRmV25grYrO+6efT9m+15ekw8AT5qsrOiF0OBbq74pgN2YHAVFifHcieAXrga5TrsUn7kff2nPgsBJcGJVyc1SMgQhL1kTP/Ldu+AH+fJWYPM3L/MzX/INjvP7G/M6f+sWT/E+D9lWHvTlzfOue/RMj/SJXvFOn8D/KF4IHF71Vn/1jgAKWL/1XI/1TR/1Dw72Ty/2JE/2KW32+y3zRQ/haJ/2I7/2/N32XSX300z3SW/3dY/3Ea/32s33O+/3Y8/3cG/fgH/3hU/lh+/XiW/uiz/4/ej4+7j4Ui/5GSABFxBmFyABGSD5kO/fkn8CEBAAoT/6n9/5umP6w4MBiYABpf/5jO/6GkABh0ABGtD6ro/6w2MBh2ABt+/6iO/7FXAIFdD7xO/7JBABARABvo/78m38JTABATAByz/9zn/8xs/8+F392v/7h4/9218P3g8O4T+4XV/+lhD5xQ/fcTD+ZsD+q1Nk7s8D8T8G808M9X8G96/expP//7gDAoA4kqV5oqm6sq37pgE803Ur27m+8yzeA4PCYfBHPCKTxiTT13xCX8sotWoFTK/aaHaL7HrDPLC4bF6Rz2paem1ru+MkuLxepdvzy0HgIEoQDPHtBAwMOuUlluApNgoxOqrt9f0Fyh2iRSpCanayeUZO+gEAHhQC8C0QIAQEJAAcsLoCCBAIBBA0iBA4DBootArEtuoStBIsqLYqYA0UtBYA7josgtZxWmfHaCdOth6Tvia85gIwBDA0vB4oMAgUDKD2nR8M8o40WNIWJCMIpI4odMjUAYLVuElCqLAGtoVPRFVCpcCgLREBDDz7ZqDWCFsOXg0awIoAgwIGRv+MEyHglYMACgQ0w+Tx1UGHYRratIYz5xGIpCyt0gWg4oM+6khwFPFLQTxMANTlG/EuWQGYIugJDLBAhLN2JnbyJBR2bE2yXnxKA1A03tBvMIe1OpBURAFL9qAxgFvs2AI+rV4VWsCqgAgE+uaYtQI2sR7GZ13MrahmAdMTix27uIzZjebNMOCwe9DR6hkHCFB09oxatcPUrDOZdf064GyEsmt/TXx79m7cXHwz6X1GuGriwJUc/6I7eQ/jzIc45738uY7o1JtfL/JtO/fu3r+DDy9+PPjsb8xvQu/Juvrz7a+9DxUf/nzO9dPfX8M+P2z+cvb7t02AYgA4ICIGPob/4BYFKrhag1owqGCEDyJGoWIW3oHhTRpSMaGBHi5Enogjkliiid/5B2KAKtrGHIudvJhfjFs8MBEAC1T1SXJp8MHPT8fNWF+QWjSgi2kMubhCj+IcVtuQ8T1pBWUtMfBUKwgswIAsQuW2o5IXFSLNAMAocBJrUbaHZhUGBACTAFgC4M+b/QHHYx8ERBPISwD8slVxHEKh5h3xJLBdAgc0EAACZnYJ5JcHnIOLQViM4pmg5l3KRTxv+okUYZYlqQIffhSqp5sKdLpZptet+hBbibaykUYOOioqJaYEMqZLjFoK6EMNttpEsMP5KiywocpYbHADZiDBBVgAcIEEGfg2/6wZ1tYaIAQBbNttnSkqi9yAGHCHwbf8YXtugBpQ8A0FGqh7X7rVImjBNxZkK2+4yhlYwTcV5Cvkvj0pGEEAEXiJ7sBEzHvGBAFMkHCyCz/SIMIS60txERoz1vCCHAPhMcgqiHxFyWfmdKLKK7Ps3X/gjiyWTScfqB/MMedAM7SYDanzbzjnnLKqLysMtHutDR2Hz4EafXSISdtXdNMz6Lw0rTZLPbUUQqsw1xFeL6v0zVpnxrVU3+gC9hBqv8HW1QllTXbNCi3xDixVsR1E3gwTPbHcN5it0qfqcFRorAC01Io7GSEgi2iGXzSULK+88wycsGLJBx+yBlAAA8q41P+MlsSUBbfff9NJdwl2M1Cm1wmcFoBoghfU5o8onVbOOYsfQNlGcPrDB0ytV+lAAwBZNMCcoIodN+pvt4jUN5QHIgAwne/jygJJncKR9dAMZdVFSZkEuSuHsPkNYS3tWQiiivK6c9SnPw89N3V/qhIBpojmQP4AuM4S3duf7BBHGKL0gXy/69QhiGcCrLjNbhWaX8bqJyCkeQopgTBG5/hxPSxxb1MbhMYB3UILS5jESrHCxC3+4pdZFKKFkZsg1uhnwdJFjwqSMVnfKnjDRj2tCju8UPNs+EOLBG46FBTYEYGoOp71kIlNpOETHdOzsU1RfkG0YhTnY7WOJTE2XYT/UhapaJuWoTGNJBrje76oxA8hy4dZdGOH4ijFMtLxZwHzYhlpIyE78rGPWhxQHrfmvCYW8lcYu+Mcj7XIQPYxkcZ6JBkFKcmw7bGSkXRkJs3TrGfJQFrUuuEnoSXK/JQylNN6TSqjtcr2dItb3GpiLL3Fn1rOcja4hEB8yLUdcx3Rl98AZn6E2QpissaYAUAmetjlLngd0ZmteJd/pBkAas7Gmth8j71aga8pdjMA3/RPOMc5m3LWx1+tANgU1RkAdvrHnfCcjTzvY7CLZfGeCNIncPhZn4dFrIwARdBAgVNQewoSAPg00EJ909CEQjSiEp0oRWOjxouWiDcY3WhG/2HE0Y+CNKThcUS6LmlGUAzLpBtqREmlk0P5DCxTLX2NyFK6MJlmQ6VIfClJb9pTnbj0fuvxKUtzGlRt2DSmP0WD20z3pyI0tY4wQmlUi2rVERyAgylsxhEkM0TA0dQEidOeU0hWVSGUdaeawIkpvkENYbHlFDqMH5KuWhg43aJKch3CVz9zVLXYSEuVusFZg5DWQdp1BgYRCZe+ENfCIoEAdNURfq6iFXxQQ1GHG2teJhc+POWIMg+AnAHSd5GKtBABepVF/HQ6yBo1dRCVU9RWYGW7U2AuVaRFRUZkABfKFcByOALfSbuRg0mdYwG/lRxgGWBa4F7JcbyNFeRMwf9aPk2PT9cThiyowQdWeKWFnjuBZMewVOySICW2sx4WZveUdbRjFX6wmwT/kDur2GJ3P1rv/xALxdWBFyayLUDvXGejisQQeKRJ72kU4F0ZHIUdvPPdYZNag0k1I8JeQUADKjMCNm2PwKaAiTTKBFiuYsFN/wPxPURQJHMwRXNDSYADjUcC036jOudNLma5Oqp3aK+3p7UKZURyku9hz6sCwAhXCHMKJhcXjCho3QNki0IDpCR8zTAfTVRyPQJTYhBC3siVKzxUGyBXK2OGRQDeagBZJFCAImzrN0zxWD4R5s11FgkuSmImyR5iHDju7y4mS7XzAqAAeEUHV/1HgjL/HWU0KCkAqvhnwKG8Nb+MjsqT++vauiVgK60zhAwUOBUcwSTBqRKBpR29p1u8V4N0MQDyomwHtoYZAa+I9Ag4fIoCUKMocpHzCQHIqwJylcnAVgslXJyAF5+D1H+gsVdSUF6ZVZbVWjWT+gZAmSspF85ZJc2Id0FC7A6ZFlfSazyg7EeUkYDPwZBHsRNtAMFAI9XxsC2vtJpnaPhW3ArEt6fPfOHtWAUud0pbO8Qb5+QV2xngM5yd8azuzt0JL3B58LQvPgsTXFvHiV3rX2uAI0NDhtB+napSRw5TeL8BHDVooYedhuhi4RSoYeWpywGVc5SWHOgs39fPDf5UzkCW/3kkD8teidXzp7+xBRzpKwr2hpqkOxHqSLCyCw5r1q51WY/G1TnMZ0D1kGEdh9m2gtUJkfSVEHETIp37p1tgCzzVwrQYecudTlMjd2wwI3hyiR8yMl7NzjB1WtebLcBE53Fc2XoFKdOAo9sK0Rh+tYczAdwzVNEiqkC+xZZMjgzC4cpMPRBsikeORrDs9TJjbosHwjuaUmpLpCWFpvEHvd9ROxIf5vWnIgGdv5H2kH0e9Na2ytStUvpbtVl/Wj6ELRYAOcDYfrD2G/sTksL1221V0Vy5PcRrYf3snmJUnA8705Jfw9Azf4OZphwlfC3C6ePAFiCOE/YvLfu1J4H3lf/aaeyDRJyEA+Bd7xFb3l2WrjWaynWeVLmf062AZHBE+tDalSwcLTTcBglY/nEXNAAGNByfhTWBAMKYKxyA5bgOP5xDBtbbAMFFNGABCZ5ABIrdBBJIFb1cuLgW0fHgzfnKD/pgEM7egxChstSU0SmhDlIgUjEhDJxdCUyh3S2YDrQd/+1Ai9maE0ogFA4dDVShpOXAGC6frKnAm/3BNyBAXJnQjdgWNRSZ2nlh3IHh0tWAGWpZGV5hDrRdAcxOlhWKXp1EUWxF42yFSIjAR9BhHXYI3UGiCXpctMnD9nwDA6DWuknOX2zix3EQMoxOAOgC4p3EKnDic2WPokhXJoL/g8QlHpv5SZY9RWYdGTPwWAnUSCM6Yh0aASV23Dj4YvjolzToDjoQQK4kED8IhgAsj0UM3zHKQ6WAmO+VGzEKACVyhInl4gg4A0p0GUewYVOonCno4i46oRG4m0QQRDrq36d0o2SkG0Fk2Uq8z6L42J3w3QHoWVyE0Ogt2afUQvE1G295Y49dBJWZw0Bi1RIkoTmWXTBKji4Eo6ZVSVQg0LixmVwoY+sV4Ck4WkUQxLIJWz82n35FhYmZgCnEIk0Uih9Ezt/FCQL4gSKeWBc6pPvVzSUyG1vIECa6iSZykO2AJCV8oiUeTrdpGUE43LCVnweSwpXkiuGVACCuoSZifIGZUCMHOdgisl9D3iTUVF2TsIAexsDxIYEa7sAc2uRXVhQZhIbZ9eFnmCUSOKAOcOG7sSUvElVe6mXL8aUXemUO/iVO7uVgTmBgtp9hHmYkMmZjnohiQmZkSuZkUmZlWuZlYmZmauZmcmZneuZngmZoiuZokmZpmuZfhgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MGUS: monoclonal gammopathy of undetermined significance; WM: Waldenstr&ouml;m macroglobulinemia.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenstr&ouml;m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85:824. Copyright &copy; 2010 Quadrant HealthCom, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27710=[""].join("\n");
var outline_f27_3_27710=null;
var title_f27_3_27711="Gram stain peritoneal fluid";
var content_f27_3_27711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain peritoneal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_3_27711=[""].join("\n");
var outline_f27_3_27711=null;
